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PR  HIV protease 
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SP2  Spacer protein 2 / p1 
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TPV  Tripanavir 
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2 ABSTRACT 
In Switzerland and Germany up to a half of the first-line regimens include 
protease inhibitors (PIs) [1, 2]. Although in the Swiss HIV Cohort Study (SHCS) 
most patients under antiretroviral therapy (ART) have suppressed viral loads [3], 
every third patient is or has been affected by drug resistances [4] which are one of 
major causes for therapy failure. 
HIV resistance against PIs is typically characterized by the accumulation of 
structural alterations in the viral protease (PR). However, a number of cases of 
clinical therapy failure under PI-containing regimes have been reported, where 
genotypic resistance testing did not reveal sufficient explanation from information 
on the PR and regimen compliance [5, 6]. And certain alterations in the natural 
substrate of the PR, Gag polyprotein, have been associated with the development 
of PI resistance [7-13]. Nevertheless, until today most algorithms evaluating PI 
resistances take solely the protease gene itself into account. 
In the SHCS protease inhibitor use and successful treatment are monitored 
regularly for all patients and every newly enrolled patient receives a genotypic 
resistance test. We used in vivo cross-sectional sequence data from SHCS patients 
to scrutinize PI resistance mutational pathways across Gag and PR. Roles of 
certain mutations as well as of their interactions were investigated. 
Here we demonstrate that roughly every fifth of the SHCS patients carries 
resistance mutations in Gag. And since Gag is not considered by the current 
genotyping systems the overall level of PI resistance for these patients is 
underestimated. We report novel Gag mutations of potential clinical relevance and 
provide additional details on known resistance mutational patterns. Additionally 
our data support a new potential role of p6 alterations in PI resistance mediated by 
its phosphorylation. Taken together, our results suggest the relevance of Gag 
sequence information for the routine genotyping of PI-treated patients of the 
SHCS.  
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3 INTRODUCTION 
3.1 Human Immunodeficiency Virus 
3.1.1 Structure 
HIV virions have a spherical morphology typical for most retroviruses 
(Figure 1), and the particle diameter is around 130 nm [14]. The external proteins 
gp120 are non-covalently associated with the transmembrane proteins gp41. Both 
gp120 and gp41 carry polysaccharide modifications. They are functionally active 
as trimeric complexes and responsible for target cell attachment and fusion. 
Observed numbers of such complexes vary between 4 and 35 [15], but more recent 
publications report 10 complexes per particle [16]. They tend to cluster in the 
mature viral particles but seem to be located randomly in the immature virions 
[17]. Gp41 proteins penetrate the membranous viral envelope, which originates 
from the cytoplasmic membrane of the host cell, and inside the membrane reach 
for the matrix proteins that cover the conical capsid of the virus. The contact 
between the envelope and the matrix trimeric proteins is provided by amino-
terminally attached myristic acid residues [18]. Details about the contact between 
envelope proteins and matrix proteins is still under discussion [19]. Mature matrix 
proteins then form a lattice-like layer, which, at budding, becomes responsible for 
the shape of the virion. 
The central core of the structure is represented by the conical (the shape is 
characteristic of the genus Lentivirus) capsid. It is built of matured capsid protein 
oligomers and protects two single-stranded RNA molecules. The RNA strands are 
associated with nucleocapsid proteins but neither possess covalent link between 
them nor exhibit any base-pair contact. HIV virions also include: Additional 
cellular components such as cyclophilin A bound to the capsid, actin, APOBEC3G, 
tRNA [20] and 7SL RNA [21]; essential virus-encoded enzymes, in according with 
features of the lifecycle: reverse transcriptase, integrase and protease; accessory 
proteins and factors, i.e. Tat, Vif, Vpr, Nef. 
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Figure 1. Structure of a mature HIV virion. Illustration by Th. 
Splettstoesser [22]. 
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3.1.2 Genome organization 
 
The HIV-1 genome is comprised of two linear plus-ssRNA molecules, both 
5’-capped and 3’-polyadenylated, matching the key properties of eukaryotic 
mRNA. Each molecule is typically 9-10 kb in size and contains (Figure 2): Three 
genes encoding for viral structural proteins typical for all Retroviridae: gag, pol 
and env; two genes encoding for regulatory elements: tat and rev; four genes 
encoding for accessory regulatory proteins: vpr, vif, nef and vpu. 
Encoded by the gag gene (corresponds to Gag protein, “group-specific 
antigen”) are: matrix (MA / p17), capsid (CA / p24), spacer protein 1 (SP1 / p2), 
nucleocapsid (NC / p7), spacer protein 2 (SP2 / p1), and the p6 protein. Encoded 
by pol gene (corresponds to Pol protein, polymerase) are: protease (PR), reverse 
transcriptase (RT / p51), RNase H (p15), integrase (IN / p31) and transframe p6 
protein. Envelope glycoproteins gp120 and gp41 are encoded by env gene and are 
synthesized as the protein precursor gp160. 
Regulatory elements are responsible for transactivation while accessory 
proteins represent virulence factors [23]. Both 5’ and 3’ ends of the sequence 
harbor key elements necessary for reverse transcription and consequent integration 
of the viral DNA into the host chromosome: R (“redundant”) is the fragment of 
identical sequence and orientation at the 3’ and 5’ termini; U5 (“unique”) is located 
at the 5’ terminus and is required for the correct integration process; PB is site 
responsible for the attachment of the 3’ end of a Lys-tRNA molecule; Leader 
region with splice donor site; a polypurine tract is required for the initiation of the 
second strand DNA synthesis during reverse transcription; U3 region, which is a 
U5 analog but is positioned at the 3’ terminus of the LTR and is followed by the R 
fragment. The complete Long terminal repeat (LTR) which regulates the gene 
expression is formed during reverse transcription of U3, R and U5 and represents 
the 3’ and 5’ ends only of the reversely transcribed genome.  
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Figure 2. HIV-1 genome organization. Open reading frames are shown as rectangles. The gene start, indicated by the 
small number in the upper left corner of each rectangle records the position of the a in the ATG start codon for that gene, while 
the number in the lower right records the last position of the stop codon. For pol, the start is taken to be the first T in the sequence 
TTTTTTAG, which forms part of the stem loop that potentiates ribosomal slippage on the RNA and a resulting -1 frameshift and 
the translation of the Gag-Pol polyprotein. The tat and rev spliced exons are shown as shaded rectangles. Illustration from Los 
Alamos HIV Database [24]. 
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3.1.3 Replication cycle 
 
In order to initiate a new infection, the mature HIV viral particle has to 
attach to the target cell of T-cells or macrophages (Figure 3). This happens through 
the primary receptor CD4 as well as chemokine co-receptors CCR5 and CxCR4. 
Preferred co-receptor determines viral tropism with CxCR4 generally 
corresponding to T-cell-line tropic viruses (lymphotropic / X4 / “TCL”-tropic) and 
CCR5 – to the viruses replicating in macrophages (R5 / “M”-tropic). From the 
viral side, attachment is mediated by the envelope protein complexes. Their 
interaction with above-mentioned cellular receptors and conformational 
rearrangements allow entry of the virus capsid into the cell through the fusion 
between the viral envelope and cell membrane. This may reduce the effects of 
ART by allowing new infections to happen independently of production of 
infectious viral particles [25-28]. 
At this stage the viral capsid has to partially disassemble so reverse 
transcription process can be initiated in the cytoplasm. DNA is synthesized on the 
RNA matrix with the help of Lys-tRNA annealing to PB as a primer. Then this 
DNA binds to the U5 and R region of the RNA. RNase H removes U5 and R 
region of the RNA. Then the primer relocates to the 3’ end of the viral genome 
which allows the extension of the first strand cDNA. After majority of viral RNA 
is degraded by RNase H the leftovers prime the synthesis of the second strand. The 
relocation happens when the two strands hybridize with their PB sequences which 
allows the extension for both of them. 
Still bound to the viral components, dsDNA is then transported as a 
preintegration complex into the nucleus through the nuclear pores. Vpr, MA and 
cellular nuclear import factors are the key players at the stage. IN generates a 5’ 
end overhang at both LTR by digesting a dinucleotide from the both 3’ ends of the 
dsDNA. The enzyme also inserts a cut at a random site of the host DNA with 
overhangs at 5’ termini. The 3’ ends of the viral DNA genome then bind covalently 
to the 5’ ends of the host DNA via phosphodiester bonds after which viral 5’ 
10 
 
overhangs can be removed and single-stranded gaps are repaired by cellular 
systems. DNA ligases finish the process by adding missing covalent links. 
After the first full-length mRNA is transcribed from the integrated provirus 
and spliced, Tat protein is translated and transcription rate of viral mRNAs is 
dramatically increased. This is explained by Tat being imported into the nucleus 
and binding to the TAR elements at the 5’ termini of viral mRNAs. It has a 
stabilising effect and allows for efficient elongation. Variously spliced and 
unspliced mRNAs allow for production of (Figure 4): Tat, Rev and Nef; Vif, Vpr, 
Vpu and envelope proteins; structural and enzymatic viral components. Full-length 
unspliced mRNA are simultaneously used as viral genomes to be packaged into the 
particles. 
Envelope proteins are initially translated as gp160 on the endoplasmatic 
reticulum. Then during the transport through the Golgi complex to the surface of 
infected cell gp160 is cleaved by cellular proteases into gp120 and gp41. 
Fusogenic activity of their complexes on the cell surface allows the virus to infect 
neighbouring cells in particle-independent manner. 
Products of gag and pol genes are initially translated as Gag and Gag-Pol 
polyproteins on cytoplasmic ribosomes. Then the polyproteins are myristoylated at 
their p17 end and transported to the place of particle assembly, which is the 
cytoplasmic membrane in case of T-cells but can be intracellular membranes in the 
case of macrophages and monocytes. Gag and Gag-Pol polyproteins and their 
domains orchestrate the assembly and packaging of all components of the viral 
particle [29] which allows subsequent budding. 
PR as a domain of Gag-Pol protein initiates autocatalytic process to excise 
itself. After that it produces cleavages at a number of fixed sites across the Gag and 
Gag-Pol polyproteins in order to transform precursor proteins into the proteins that 
build up the mature viral particle. This occurs when a particle is liberated from the 
host cell, and this step is necessary for the structural rearrangements that lead to the 
morphology of infectious virion. 
The roles HIV proteins are summarized in the Table 1.
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Figure 3. Scheme of the HIV replication cycle. Viral and cell components are labelled in italics, processes in plain text, 
and processes that can be inhibited by current antiretrovirals are boxed. MA, red; NC, green; p6, orange; Env, purple; viral RNA, 
cyan; viral cDNA, brown. Illustration by Tedbury and Freed [30]. 
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Figure 4. HIV-1 splicing patterns. The genomic organization of the proviral DNA and the location of protein coding 
sequences are indicated. The dashed lines connect the major splice donor to a downstream splice acceptor. Adapted from Fields, 
Knipe and Howley [31]. 
13 
 
Table 1. HIV proteins and their respective roles. Adapted from Votteler 
and Schubert [32]. 
Protein  
class 
Gene Product 
Processed 
product 
Role 
Structural 
gag 
Gag  
polyprotein 
MA, CA, SP1, NC, 
SP2, P6 
Virion assembly 
pol 
Gag-Pol  
polyprotein 
TF P6, PR, RT, 
RNase H, IN 
Genome replication 
env gp160 gp120, gp41 Attachment and entry 
Regulatory 
tat Tat Tat 
Positive regulator of LTR 
transcription 
rev Rev Rev 
Regulator of viral gene 
expression: splicing and transport 
Accessory 
nef Nef Nef 
Downregulation of CD3, CD4 and 
MHC-1, signalling and T-cell 
activation, apoptosis, infectivity 
enhancement 
vpr Vpr Vpr 
Virus associated membrane 
transduction, nuclear import of 
preintegration complex, 
differentiation, cell cycle arrest 
and apoptosis, regulation of 
glucocorticoid receptor 
vif Vif Vif 
Infectivity factor: suppression of 
antiviral activity of APOBEC3G 
(cytitine deaminase) 
vpu Vpu Vpu 
Augmentation of virus release, 
CD4 degradation, inhibition of 
NF-κB activation 
  
14 
 
3.1.4 History, diversity and classification 
 
First clinical observations of the acquired immune deficiency syndrome 
(AIDS) were made in1981 in USA among an MSM cohort patients suffering from 
opportunistic infections [33]. And already in 1983 HIV was discovered as a 
causative infectious agent of AIDS by the two independent groups of Luc 
Montagnier and Robert Gallo [34, 35]. Several years passed before the term “HIV” 
was commonly accepted. 
HIV belongs to the family Retroviridae, subfamily Orthoretrovirinae, 
genus Lentivirus. One of its characteristics is its high genetic variability that results 
from three major reasons: missing proofreading activity of the RT, that leads to 
high mutation rate (3x10
-5
 per nucleotide base per cycle of replication); copy-
choice recombination due to the ability of RT to switch between 2 RNA templates 
of a viral particle, which are not necessarily of identical sequence (2-20 events per 
genome per replication cycle); fast replication cycle (10
10
 virions a day) [36-38]. 
These factors along with the genome size of HIV allow multiple alterations at 
every nucleotide position every day. This is the basis of the observed vast viral 
diversity along with a rapid selection towards resistance under ART. 
Two types of HIV have been described: more virulent and infective HIV-1 
that causes most of the HIV infections and its less transmissive counterpart HIV-2 
mostly observed in West Africa region [39, 40].  
HIV-1 originated from Africa as a result of zoonotic transmissions of its 
phylogenetic “relative” SIV to humans. Natural SIV hosts, different simian 
species, generally do not develop disease upon infection. SIVcpz is considered to 
be the direct ancestor of HIV-1; this virus can cause AIDS-like symptoms in 
chimpanzees [41]. Sequence difference up to 30% allows classification of HIV-1 
onto three major groups: M (major), O (outlier) and N (new / non-major) [42]. 
Group M isolates represent most of all cases of HIV infection. In this group several 
subtypes (or clades) have been identified: A, B, C, D, F, H, J and K [43]. They 
have different prevalence over geographic regions, and subtypes B and C are the 
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most frequent in the M group. Recombinant circulating forms (CRFs) have been 
also described and are the result of co-infection with the viral variants of different 
subtypes. 
HIV-2 is phylogenetically distant from HIV-1: sequence difference can be 
as high as 40%. It is thought to have originated from SIVsmm that 
asymptomatically infects West-African sooty mangabey monkeys. This group can 
also be subdivided into subtypes: from A to H. 
Since the discovery of the pathogen causing AIDS both basic and clinical 
research advanced extremely. Today one can effectively diagnose HIV infection 
and suppress viral replication using ART; HIV itself and the process of its 
pathogenesis are well understood [44, 45]. There has been also a major progress in 
decreasing HIV transmission, particularly mother-to child transmission [46]. 
There are three main avenues along which the healthcare community is 
now moving towards the goal of ending the HIV pandemic [47]: Complete and 
comprehensive global implementation of available treatment and prevention tools; 
research on elimination of the virus in patients or control of infection not 
dependent on lifelong ART; development of novel potent prevention tools that 
could complement and enhance the ones available currently. 
Yet by the end of 2013 around 39 million people globally have died from 
HIV-related causes, and HIV infection continues to be one of the major unsolved 
global health problems as there is still no cure for the currently 35 million people 
living with it and for around 2 million newly infected (figure from 2013 [48]). In 
20 years from 1990 to 2010 it went up in global ranks for causes of disability-
adjusted life years from 33rd to 5th place [49, 50]. 
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3.1.5 Infection, pathogenesis and clinical features 
 
The clinical course of the disease is summarised in Figure 5 and generally 
divided into three phases: primary infection, latency (chronic infection) and AIDS. 
Infection is carried out by mature HIV particles or virus-infected cells [25-
27]. They get into the vaginal or intestinal mucosa and into the bloodstream 
through sexual contact or injuries. HIV initial targets are Langerhans cells of the 
skin, dendritic cells and macrophages. The latter ones allow the virus to establish 
reservoirs for long-term persistence. T lymphocytes are usually considered to be 
inoculated later. Infected cells travel through the lymphatic vessels and 
bloodstream. Lymph nodes with their dendritic cells represent a viral reservoir 
where monocytes, macrophages and primary T lymphocytes get infected. 
Macrophages also allow transportation of virus to the brain and other organs and 
infection of other cell types like astrocytes and endothelial cells. 
Only one third of all HIV infections are described to manifest with the 
typical flu-like symptoms, unspecific rash and swollen lymph nodes in the first 
phase or “primary infection” several weeks after exposure; most cases are 
clinically unapparent. Up to 10
6
-10
8
 viral genome copies per millilitre of blood can 
be detected with quantitative PCR method at this stage. CD4 cell level drops below 
500 cells per microliter of blood, and the CD4/CD8 ratio shifts below 0.5. Duration 
of several initial months is characteristic for this phase. Chronically unapparent 
infection or clinical latency may characterize a very prolonged (for up to more than 
two decades) phase often with no or mild observable symptoms: fever, weight loss, 
diarrhoea, fatigue and coughing may occur. One to three months post infection 
HIV-specific antibodies and T-lymphocytes can be detected. Viral load goes down 
often to only several thousand genome equivalents per millilitre of peripheral 
blood. Spleen, tonsils and Peyer patches are also the sites of viral replication 
during the stage. Viral proliferation occurs but still under control by the immune 
defence. 
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When CD4 cell level decline cannot be compensated by the differentiation 
of the bone marrow progenitor cells anymore, the control is lost. Damage to the 
CD4 cell population leads to the failure of associated immunological functions; 
CD8 lymphocytes are not indirectly activated anymore. HIV genetic variability 
also complicates immune recognition due to the alteration of epitopes. The 
immune system malfunction allows the development of opportunistic infections. 
The time when the CD4 cell count falls below 200 cells per µL of blood is the 
onset of clinical AIDS symptoms accompanied by fever, nocturnal sweating, 
swollen lymph nodes, weight loss and sometimes neurological problems. 
There are several reasons for the loss of CD4 cells: Direct elimination by 
viral replication through necrotic pathway [51], mostly affects CD4 T 
lymphocytes; apoptotic processes induced by Tat expression, by cytokines and 
chemokines generated by infected macrophages and monocytes, and by gp120-
antibody complexes bound to the uninfected cells; elimination by cytotoxic CD8 
lymphocytes.
18 
 
 
Figure 5. Clinical progression of HIV infection. The black curve represents 
the time course of the number of CD4 cells per microliter of blood; the red curve 
shows the number of viral genome copies per millilitre of blood. The time axis 
includes the first few weeks of infection up to a period of more than 10 years. 
Figure by Modrow et al. [52]. 
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3.2 Gag, protease and protease inhibitor resistance 
3.2.1 Gag structure and function 
 
Initially recognized as a simple scaffold protein forming the viral particle, 
Gag has been shown to perform multiple functions in the HIV lifecycle and to be 
involved in multiple interactions with both cellular and viral components. 
Therefore today it is considered to be an emerging therapy target. 
Gag or Pr55
Gag
 (Figure 6) and Gag-Pol polyproteins are translated from the 
full-length RNA which serves as both the genome to be included into assembling 
viral particles [53]. Gag and Gag-Pol are produced at a rate of approximately 20:1. 
This is facilitated by the ribosomal slippery site in a uridine-rich region of the 
mRNA corresponding to the transframe p6 fragment [54]. In case of a frame-shift 
most of p6 is left out and PR, RT, RNase H and IN sequences are translated. Once 
Gag and Gag-Pol have been produced in the cytoplasm of a host cell they are 
guided by MA to the cholesterol-rich microdomains of plasma membrain [55, 56].  
And such behaviour of MA is driven by its membrane-binding domain which 
includes an N-terminal covalently attached myristic acid and a basic region [18, 
57-59].  
Then binding of viral genomic RNA with NC domain of Gag renders Gag 
multimerization and assembly of the immature viral particle [60, 61]. The RNA 
association occurs via the overall positive charge of the NC Gag domain. And the 
specificity for the viral genomic RNA results from a direct interaction of the RNA 
packaging signal with two extremely conserved zinc finger motifs within the viral 
NC [61, 62]. 
CA as a part of Gag polyprotein is responsible for intermolecular 
interactions facilitating Gag multimerization and particle assembly [63]. The C-
terminal domain (CTD) of CA containing a well-conserved major homology 
region is essential for this assembly process [64, 65]. The N-terminal domain 
(NTD) of CA carrying a proline-rich loop binds cyclophilins, in particular 
cyclophilin A [66]. It has been suggested that cyclophilin A binding to the capsid 
20 
 
core protects HIV-1 from being recognized by the cellular innate immune response 
[67]. 
Then glycosylated trimers of the Env glycoproteins (3 x gp120 + 3 x gp41) 
are incorporated into the immature Gag carcase through interaction of gp41 with 
MA [19, 68, 69]. Their origin is described in details elsewhere [19]. 
Further particle budding and release depends on the membrane scission 
which is also mediated by Gag. The p6 fraction of Gag contains two so-called late 
domains necessary for the recruitment of endosomal sorting complexes required 
for transport (ESCRTs: ESCRT-0, I, II, and III) to perform the scission. Normal 
functions of ESCRTs are discussed elsewhere [70, 71]. One of the late domains is 
Pro-Thr-Ala-Pro (PTAP) motif that binds directly to the ESCRT-I component 
Tsg101. Another late domain, Tyr-Pro-Xn-Leu sequence (YPXnL, where X may 
be any residue, and n = 1–4 amino acids) interacts with ESCRT-associated factor 
ALIX. The main late domain is PTAP motif [72-74], but YPXnL motif is 
indispensable for HIV-1 replication in some cell types [75]. 
Gag and Gag-Pol cleavage is performed by the PR resulting in the release 
of mature Gag and Gag-Pol derived proteins: MA, CA, SP1, NC, SP2, p6, PR, RT, 
RNase H, IN. This triggers viral particle maturation which happens during or 
shortly after the release of immature virion [63]. Maturation enhances the 
fusogenic potential of Env protein complexes [76, 77] and allows formation of MA 
lattice and mature CA conical core [16, 63]. MA forms hexamers of trimers so that 
the MA trimers orient themselves on top of the underlying hexameric lattice 
formed by CA [78]. Certain mutations in MA can completely block the 
incorporation of HIV-1 Env. Such block of Env incorporation can be rescued by 
truncations and alterations in the cytoplasmic tail of gp41 or by heterologous short-
tailed Env glycoproteins. Efficiency of incorporation of the truncated HIV-1 Env 
depends on the cell type studied [79, 80]. Additional mutations at the MA trimer 
interface could compensate some of MA mutations that cause Env incorporation 
block. So MA trimer formation is suggested to play an important role in Env 
incorporation [81]. 
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The structure of the hexagonal CA core is sealed with seven CA pentamers 
at the wide end and five - at the narrow end. Both CA hexamers and pentamers are 
formed based on NTD-NTD and intermolecular NTD-CTD interactions. At the 
same time CTD-CTD interactions allow the formation of the broad hexamer lattice 
[82]. Alterations of CA amino acid sequence have been shown to affect capsid core 
stability and influences virus infectivity [83]. Such rearrangements can be clearly 
seen on the pictures from electron microscopy of immature versus mature virions 
(Figure 7). Mature viral particles at this stage are finally ready to infect target cells 
and initiate another round of infection. 
Gag derivatives additionally play an important role in post-entry events. So 
NC also functions as a nucleic acid chaperone which promotes reverse 
transcription and downstream stages of the viral lifecycle [60]. 
A further role of CA is its participation in processes of reverse transcription 
along with MA [84, 85]. CA interacts both with cellular transportins and nuclear 
pore components (karyopherin TNPO3, nuclear pore proteins Nup153 and 
Nup358) to control the nuclear import of pre-integration complex [86-88]. In line 
with this CA is considered to be a factor allowing lentiviral infection of non-
dividing cells [89]. Cyclosporin A prevents the binding of cyclophilins to CA. This 
impairs HIV-1 replication [66, 90]. It has been suggested that by blocking the 
binding of cyclophilin A or Nup358 to CA, cyclosporin A can “unmask” the viral 
core, allowing it to be recognized by restriction factors [91] or other components of 
the host innate immune response [67]. 
A role of p6 as a Gag domain relevant for post-entry events is the 
recruitment of the HIV-1 accessory protein Vpr into a virion with the help of a 
specific binding sequence. Vpr impacts viral replication and pathogenesis. It 
participates in guiding of pre-integration complex to a nuclear pore and subsequent 
nuclear transport [92, 93]. 
As for the spacer peptides of Gag, they regulate kinetics of Gag processing. 
SP1 in addition forms part of the sequence following the C-terminus of CA which 
is crucial for Gag-Gag interactions at the particle assembly stage [94-96]. 
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Figure 6. Schematic drawing of HIV-1 Gag indicating major functional motifs. The myristic acid and highly basic region 
of MA mediate membrane interactions of Gag. Residues in MA that have been shown to affect Env incorporation are indicated 
with dashed vertical lines. CA is divided into N-terminal and C-terminal domains, NTD and CTD, respectively. The NTD 
promotes pentamer formation, while the CTD, which also contains the major homology region, is required for CA dimerization 
and multimerization. NC contributes to Gag assembly by binding nucleic acid, typically the viral genome, via its zinc finger 
motifs, leading to long-range Gag multimerization. The p6 contains the late domains PTAP and YPXL, which bind TSG101 and 
ALIX, respectively, thereby recruiting the ESCRT machinery to facilitate virus budding from the cell membrane. MA, red; CA, 
blue; NC, green; p6, orange. Spacer peptides SP1 and SP2 are indicated, as is the approximate length of the Gag precursor (500 
amino acids). By Tedbury and Freed [30]. 
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Figure 7. Effects of maturation. Transition between the immature, not 
infectious, and mature, infectious, state is initiated by the viral protease cleavages. 
Nothing new enters the viral particle at this stage, only rearrangements take place. 
Spherical shell of Gag and Gag-Pol polyproteins is converted into well-
differentiated structures of infectious virion. Illustration was kindly provided by 
Th. Klimkait. 
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3.2.2 HIV-1 protease 
 
The HIV-1 protease is critical for the viral life cycle. It initiates maturation 
of produced viral particles as described above. The natural substrates of PR are the 
Gag and Gag-Pol polyproteins that provide the virus with the key structural and 
enzymatic components. The HIV-1 protease functions as a homodimer. It is a 
retroviral aspartyl proteinase [97] with the active center including aspartic acid 25, 
threonine 26 and glycine 27 [98-102]. Though PR is a small protein and carries out 
critical function in viral maturation and infectivity, it possesses notable plasticity, 
and polymorphisms have been observed in one-third of its 99 amino acids [103, 
104]. Three functional domains can be identified in the PR structure: active site 
cleft, two flaps above it and a dimerization interface [105]. 
HIV-1 PR possesses some activity already as a domain of Gag-Pol 
polyprotein. However such PR dimers are unstable and much less active than the 
released, excised form of protease. This is because embedded PR adopts the proper 
conformation only for short periods of time [106-108]. Initial intramolecular 
cleavage events are: SP1/NC then internal transframe protein cleavage site and 
transframe protein / PR cleavage site [108-111]. Now, liberated from one side, PR 
can gain proper conformation and therefore stability and catalytic activity[112]. 
Now cleaving becomes intermolecular and the PR monomers are completely 
liberated from the Gag-Pol precursor [113, 114]. 
When the N-terminus of the PR is bound it cannot cut intermolecularly 
[111], therefore Gag processing occurs subsequently to PR dimer maturation. The 
process of cleavage is highly specific and temporally and spatially regulated 
(Figure 8, Figure 9). However, PR needs to be somewhat promiscuous as it 
recognizes 12 Phe-Pro and Tyr-Pro containing cleavage sites (none of which is 
efficiently cleaved by mammalian proteases) with their individual sequences [54, 
115-117] (Table 2).  The order of cleavage is determined by the relative processing 
rates of individual cleavage sites. The “fastest” cleavage site SP1/NC is processed 
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400 more effectively than the “slowest” cleavage sites CA/SP1 and NC/SP2 [118-
121]. And processing efficiency of each individual cleavage site is thought to 
depend in a complex way on its amino acid sequence, time of accessibility to the 
active center of the protease, formed shape, conformation of surrounding protein 
and contextual cues [96, 122, 123]. 
 
Table 2. HIV-1 M-group PR cleavage site decapeptides. TFP – transframe 
protein. 
 Site  P5  P4  P3  P2  P1 ✄   P1'  P2'  P3'  P4'  P5'
 MA/CA V S Q N Y / P I V Q N 
 CA/p2 K A R V L / A E A M S 
 p2/NC T S A I M / M Q R G N 
 NC/p1 E R Q A N / F L G K I 
p1/p6
gag
  R P G N F / L Q S R P 
 NC/TFP E R Q A N / F L R E N 
TFP/p6  
pol
E D L A F / L Q G K A 
p6
pol
 /PR V S F N F / P Q V T C 
 PR/RTp51 C T L N F / P I S P I 
 RT/RTp66 G A E T F / Y V D G A 
 RTp66/INT I R K V L / F L D G I 
 Nef A A C A W / L E A Q E 
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Figure 8. Gag polyprotein processing via ordered cleavages by PR. The 
order indicated at the top of the figure by the numbers over the cleavage sites is 
determined partly by the intrinsic processing rate of each cleavage recognition 
sequence and partly by preceding cleavages at neighboring sites. By Salzwedel, 
Martin and Sakalian [124]. 
 
 
Figure 9. A model representation of the step-wise processing of HIV-1 
Gag by the HIV-1 protease. Gag, comprising MA (blue), CA (green), SP1 (light 
green), NC (red), SP2 (tan), and p6 (gray), is extended in a radial orientation from 
the membrane (gold), as is Gag-Pro-Pol, which contains the viral enzymes PR 
(brown), RT (blue–gray), and IN (purple). By Potempa et al. [125]. 
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3.2.3 Maturation inhibitors 
 
There are two principle ways to block Gag and Gag-Pol cleavage by the PR 
and therefore prevent initiation of the maturation stage of viral lifecycle: to target 
the enzyme or the substrate. The former option is carried out by the protease 
inhibitors while the latter one – by maturation inhibitors. 
Maturation inhibitors disrupt Gag cleavage. The currently only drug of the 
class, bevirimat, binds to and blocks the CA/SP1 cleavage site from being accessed 
by PR. Even if it occurs in an incomplete fashion, such a disruption causes the 
accumulation of a p25 precursor (see Figure 8) and loss of infectivity [126, 127]. 
Bevirimat, a derivative of betulinic acid (isolated from Syzygium claviflorum), was 
the first (and by now the only) compound of the class, which reached phase IIb 
clinical trials. It causes aberrant virion morphology and replication defects [128]. 
The compound proved to be safe with only mild and rare side effects such as 
headaches and throat discomfort [124, 129]. However, a large fraction (roughly 
half) of patients carried viruses with amino acid polymorphisms at the bevirimat 
binding site (SP1 residues 6–8 / Gag residues 369-371) that rendered the virus less 
susceptible to the drug [130, 131]. Some of the resistance mutations revealed 
subtype-specific consensus. Work on bevirimat as a potential therapeutic agent was 
discontinued due to the high prevalence of resistance-conferring polymorphisms 
[132-134]. Furthermore, it became obvious that only liquid formulation provided 
adequate drug levels, and such formulation is undesirable for commercial 
development. 
Another chemically unrelated molecule, PF-46396, demonstrated similar 
anti-HIV effects mediated by a related mechanism applied to the same cleavage 
site. Its development encountered the same problem of resistance mutations 
clustering in the CA/SP1 junction region [135, 136]. 
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3.2.4 Protease inhibitors 
 
Since PR is indispensable for the HIV viability it represents extremely 
attractive and well-studied drug target. The substrate-mimicking compounds of the 
protease inhibitor class bind to the PR enzyme and, in contrast to maturation 
inhibitors, therefore block any stage of Gag and Gag-Pol processing. Nine PIs were 
approved for the treatment of HIV infection: saquinavir, ritonavir, indinavir, 
nelfinavir, amprenavir, lopinavir, atazanavir, tipranavir and darunavir (Figure 10). 
Low doses of ritonavir were used for boosting (to slow down metabolism of the 
drugs making up a regimen backbone).  
The development of PI enabled the dual class triple combination therapy 
that became known as highly active antiretroviral therapy (HAART) [103, 137, 
138]. All PIs except TPV are essentially analogues of the transition state of a 
natural PR substrate [139, 140]. They mimic a cleavage site recognized by the PR, 
but instead of natural and hydrolysable P1-P1’ amide chemical bond they carry 
non-hydrolyzable transition state isosteres [141]. PI possesses special and distinct 
features compared to the compounds of other classes. One feature of PI is their 
cooperative inhibition of PR:  Minor reductions in drug concentration or 
effectiveness cause nonlinear decreases in inhibition [125, 142-144]. This results in 
the steeper slopes of inhibition curves. A second feature is pleiotropic effect of the 
compound of the class (Figure 11): PIs are able to interfere with viral function at 
multiple stages of the viral lifecycle [145] (fusion [76, 77, 145, 146], reverse 
transcription [147, 148], nuclear import and integration [145]). The ability of PI to 
affect fusion might be mediated by HIV Env proteins. Since uncleaved Gag is 
stably linked to Env trimers [149] block of maturation prevents mobility and 
formation of a single cluster of Env molecules on the surface [17] which results in 
reduction of infectivity and fusogenic potential [76, 77, 146]. Several studies find 
the link between fusion and PR inhibition to be cell-type dependent [145] and co-
receptor dependent[146]. PI is suggested to also affect the reverse transcription 
process in two ways: by decreasing RT activity and by interfering with the 
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assembly of the ribonucleoprotein (RNA and NC) and therefore a reverse-
transcription complex. A simple way of PI control over initiating RT activity is by 
trapping RT in a precursor form where its activity has been estimated to be much 
lower [150, 151]. And the assembly of reverse transcription complex has been 
shown to depend heavily on the sequence of proteolytic processing of Gag and 
Gag-Pol polyproteins [119, 120, 152, 153]. In addition, normal assembly of a 
reverse transcription complex has been shown to be disrupted by the accumulation 
of intermediates of Gag processing [127, 154, 155]. 
As of nuclear import and integration, there are also several ways suggested 
that allow PI interference. The most obvious is trapping IN, CA [89, 156, 157], NC 
[158, 159] and MA as components of pre-integration complex within the 
precursors [85, 160-163]. However, in such a case the virus would not even make 
it through the reverse transcription. It is currently suggested that PI could affect 
CA assembly in such a way as to allow reverse transcription to occur, but then 
compromise its ability to facilitate nuclear import [125]. Another option is the 
interference with NC functions via its precursors. It has been reported that certain 
alterations of Gag C-terminal domain amino acid sequence block processing at the 
SP2/p6 site but still allow reverse transcription to occur [164]. Wrong timing of 
SP2/p6 cleavage could enable the CA cone to assemble before condensation of the 
core producing a reverse transcription-competent, but nuclear import-defective 
virus [125]. 
A third feature of PI that extends beyond their pleiotropic effects is the 
consequence of targeting the active site of the PR itself. Because PI mimic the 
transition state of the natural substrate of PR using their characteristic hydroxyl 
group the enzyme lowers the free energy of activation for the reaction [165]. While 
binding affinity of PR to its natural substrates are in the µM to mM range [166], PI 
bind the wild-type PR in the nM to pM range [167-171], so there are several orders 
of magnitude difference. Therefore PI are considered to be relatively potent drug 
class (Figure 12). 
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Figure 10. Chemical structures of the nine HIV-1 protease inhibitors approved for clinical use. Peptidomimetic protease 
inhibitors are characterized by a hydroxyethylene core. TPV, non-peptidomimetic protease inhibitor is characterized by a 
dihydropyrone ring. By Ali et al. [172]. 
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Figure 11. Contribution of the inhibitory effect of PIs on each step of viral 
life cycle to the overall inhibitory effect at Cmax. The linear dose-response curves 
of PIs at entry, reverse transcription, and post–reverse transcription steps were 
extrapolated to predict the inhibition of each step at Cmax. By Rabi et al. [145]. 
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Figure 12. Comparison of the inhibitory constants for each inhibitor from four of the antiretroviral drug classes: protease 
inhibitors (PI), non-nucleoside reverse transcriptase inhibitors (NNRTI), nucleoside reverse transcriptase inhibitors (NRTI), and 
integrase strand transfer inhibitors (INSTI). By Potempa et al. [125].  
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3.2.5  Protease inhibitor resistance 
 
High genetic variability of HIV allows it to develop resistances against 
antiretroviral therapies applied. In patients the virus develops a number of 
genetically distinct viral variants, referred to as a viral quasispecies [173]. The pool 
of quasispecies representing viral population in a patient is capable of evolving and 
responding to different selection pressures such as immune response and therapy 
applied. 
The number of HIV variants that produces infectious progeny is relatively 
small [174-176]. Only 0.1%-1% of viral particles per generation is thought to be 
capable of carrying out new infection [177-182]. One of the reasons is the same 
mechanisms of genetic variability: make the virus to produce a high fraction of 
“dead” viruses carrying deleterious mutations. The number of resistance-associated 
mutations necessary to confer virological failure is defined as the barrier to 
resistance development [103]. But there are also other factors that have to be taken 
into account: baseline variability (groups and subtypes) and impact of the 
mutations on viral replication capacity. 
Resistance against protease inhibitors has been observed and documented.  
This stepwise process often starts with substitutions that directly or indirectly alter 
the structure of the substrate-binding cleft of PR [183-185]. And the general 
tendency of the process is to widen the catalytic cleft for the enzyme. Due to such 
enlargement inhibitors lose affinity and drug susceptibility of the mutated virus is 
reduced. On the other hand and for the same reason the binding of the natural 
substrate may similarly be impaired which can lead to losses of viral replication 
capacity or fitness [8, 186-188]. Such a process is particularly apparent for the 
main (“primary”) mutations. These are major or primary resistance mutations in 
protease. They tend to be selected first, located in the critical functional regions of 
PR, capable of reducing protease inhibitor susceptibility individually and 
extremely rare occurring in untreated isolates [104, 189, 190]. Other PR mutations 
are classified as secondary resistance mutations in protease, and in general, they 
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tend to emerge later and do not confer resistance effects by themselves in vitro. 
They are, however, capable of improving fitness of the viruses carrying primary 
resistance mutations and cooperatively enhance the degree of resistance. 
Secondary resistance mutations are usually located outside the critical functional 
regions of PR and can be observed in untreated isolates [186-188, 191].  
There are mutations specific to certain drugs (D30N - NFV, I50L - ATV), 
however cross-resistances are very common (positions: 10, 46, 54, 82, 84 and 90) 
[104, 190]. The summary primary PI resistance mutations at 15 protease codons 
and secondary resistance mutations at 19 protease codons were summarized in 
Figure 13 [189]. 
It has been recently demonstrated that a second locus can be responsible for 
the resistance against protease inhibitors and for the compensation of resistance-
associated fitness loss. Mutations in Gag located in or close to protease recognition 
sequences are more commonly found in treated viruses. They are thought to be an 
adaptation of the virus to the altered substrate-binding cleft of the mutant drug-
resistant viral protease [7, 191, 192].  
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Figure 13. Three-dimensional structure of HIV PR dimer depicting the 
primary (major) and secondary (minor) mutations associated with resistance to 
protease inhibitors. Illustration by Johnson et al. [189]. Mutated residues are 
represented with their Cα atoms (spheres) and colored red and blue for major and 
minor mutations, respectively. Active site aspartates and DRV bound to the active 
site are represented in sticks. The figure was generated using the structure of 
highly mutated patient derived HIV PR [193] (PDB code 3GGU, 
doi:10.1128/JVI.00451-09) and program PyMol [194-196]. Depicted mutations do 
not occur all together in the same isolate, this is a synopsis. 
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3.2.6 Impact of Gag mutations on protease inhibitor resistance 
 
In previous studies a number of both cleavage site and non-cleavage site 
mutations in Gag had been described to correlate with therapy failure [197-200]. 
These gag mutations have been described to associate with specific drug resistance 
profiles in the protease such as I437T/V with L76V [201], A431V with L24I-
V82A-I54V, L449F-R452S-P453L with D30N-I84V, or P453L with I84V-L90M 
[202]. Moreover, Gag mutations can directly impact on PI susceptibility. This has 
been described for mutations immediately at cleavage sites but also at non-
cleavage site positions; they have been reported to occur individually or in 
combination with further mutations; they appear in conjunction or complete 
absence of (enhancing) major resistance mutations in protease [10-13]. 
Mechanistically, alterations in Gag can restore the replication capacity of 
the affected virus, which could have been compromised by non-favorable protease 
mutations [192, 199, 203, 204]; certain Gag mutants may also retain such a 
replication advantages in the complete absence of protease inhibitor pressure [205]. 
On the molecular level Gag cleavage site mutations can exert their effect by 
affecting the processing rates of Gag cleavage sites [206], whereas non-cleavage 
site mutations could rather act indirectly through conformational changes of the 
polyprotein [13, 205]. Another likely mechanism affects functions of the mature 
cleaved Gag proteins [205].  
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4 RATIONALE AND AIMS OF THE STUDY 
 
During the last two decades an extended arsenal of highly selective and 
potent antiretroviral drugs has become available. This turned HIV infection into a 
long-term manageable chronic condition. Moreover, the recent publication of the 
WHO goals 90-90-90 aims at controlling by the year 2020 HIV replication in 73% 
of all people infected by HIV on a global scale. Today on the Northern hemisphere 
diagnosis of HIV infection and drug availability with successful long-term 
suppression of viral replication are most common. Yet, there continues to be a 
major discrepancy for lower income regions, where older drugs with massive side 
effects are still in use, or where stock-outs contribute to unavoidable therapy 
interruption.  Although HIV and the processes of its pathogenesis appear well 
understood [44, 45] mechanisms of viral escape seem to persist or even become 
more challenging among patients who are on therapy for very long [207-209]. 
Initially PIs were mainly used as part of second-line regimens. Today, 
however, up to 50% of the first-line regimens in Germany and Switzerland include 
PIs [1, 2], a number that further increases for second line regimens and beyond. 
And although in the SHCS most patients under ART have suppressed viral loads 
[3], every third patient is or has been affected by drug resistances [4]. Along with 
mal-compliance to a treatment regimen the development of viral drug resistances 
represents a key cause for therapy failure. 
The detailed knowledge of HIV drug resistance mechanisms is 
indispensable for the development of robust and cost effective suppression 
strategies. Phenotypic drug resistance testing allows in vitro evaluation of possibly 
mutated virus population from a patient. Although it deals with a direct 
measurement of drug susceptibility and is particularly suitable to assess complex 
resistance patterns like coexisting quasispecies or the presence of minority variants 
today’s standard of care is genotyping as a cheaper and more rapid approach. 
Genotyping utilizes previously obtained phenotypic information on numerous 
clinical samples and on engineered viruses paired with their underlying sequences. 
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Systems designed to interpret genotypic data and predict the therapy response take 
into account not only the presence of single resistance-associated mutations but 
also information on interactions between them [210, 211]. This is why it is crucial 
to document in details the role of as many therapy-associated mutations as possible 
and to investigate statistical, temporal and causal links between them adjusting for 
the role of natural HIV variation as well. Mechanistically, the resistance of HIV 
enzymes to certain substrate analogues is typically characterized by structural 
alterations in the viral target protein directly at the inhibitor binding site. But in 
addition to that, the viral protease offers an alternative route for the development of 
resistance – through the natural substrates of the enzyme. Earlier studies have 
shown that alterations near the protease recognition sites in Gag (“cleavage sites”) 
can accompany or are responsible for viral drug resistance. Such an alternative 
escape route of HIV was demonstrated by the viral response to the maturation 
inhibitor bevirimat, where specific modifications in the p2 motif QVT of Gag 
[134] were responsible for inhibitor failure [10, 212]. 
A number of cases of clinical therapy failure under PI-containing regimes 
have been reported, where genotypic resistance testing did not reveal sufficient 
explanation from information on the protease gene [5, 6]. Nevertheless, until today 
most algorithms evaluating PI resistances take solely the PR itself into account. 
Meanwhile, also certain Gag mutations have been associated with the development 
of PI resistance, either by statistical analysis [11, 205, 213] or in studies analyzing 
patient-derived samples after PI exposure and failure and genotyping [7-13] or 
assessing viral replication [192, 199, 203, 204]. Further details on the role of Gag 
in protease inhibitor resistance and on the mutational patterns observed in Gag-PR 
might provide an additional argument to consider the inclusion of the gag gene for 
genotyping, particularly when complex PI resistance is suspected. 
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Therefore in this study we pursued the following aims: 
1) Assess the clinical and diagnostic importance of Gag mutations; 
2) Describe Gag resistance mutations and their patterns in the HIV-1 
isolates from patients in the SHCS; 
3) Scrutinize the phenotypic impact of observed mutations. 
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5 MATERIALS AND METHODS 
5.1 Analytical part 
5.1.1 Sequences and treatment information 
 
Plasma samples were collected between 2004 and 2012 from patients in 
two centers of the Swiss HIV cohort study: Basel (n = 2022) and Zurich (n = 773). 
The ViroSeq HIV-1 Genotyping System (Abbott Molecular, Illonois, USA) 
was used for Sanger sequencing of the HIV-1 pol region in the routine diagnostics 
setting of an accredited laboratory. Pol sequences were assembled and edited using 
the ViroSeq Genotyping software v2.5 (Abbott Molecular). For details on the 
sequencing procedure, see [214]. 
The F-primer, integral part of the system, produces a read that extends in 
reverse orientation from protease into the C-terminal gag region. Although not 
accessible with the standard ViroSeq software, this information was manually 
extracted from the raw sequencing data in the form of .ab1 files and analyzed to 
obtain Gag C-terminal sequences, which are disregarded in the standard setting. F-
primer read chromatograms were processed with DNA Baser software (Heracle 
BioSoft SRL). The software performed base calling, base quality assessment, 
automatic ambiguity correction, homopolymer error correction and low quality end 
trimming. Default software settings for low quality reads were applied. Resulting 
nucleotide sequences were reverse-complemented, codon-aligned to subtype B 
consensus reference sequences [104, 190] and translated in the Gag and Pol 
reading frames using RegaDB Sequence analysis Tools [215] and Stanford HIVdb 
Program [104, 190], correspondingly. Amino acid substitutions were listed. 
Codons with more than 4 possible translations as well as preliminary stop codons 
were flagged and were excluded from statistical processing. Sequences with two or 
more adjacent flagged codons were trimmed to remove these and all the upstream 
codons. Different substitutions at the same single amino acid position were treated 
independently. We used the list and definitions of the Stanford HIV resistance 
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database for primary and secondary PI resistance mutations in the protease gene 
[104, 190]. 
Sequence information on protease and the C-terminal Gag region was 
paired with the corresponding patient treatment history. Treatment information 
came from the records on the order forms, on which the indication for resistance 
test is provided. Also the status of treatment history is categorized for each drug as 
“current” “previously” or “never”. Every sample with a status “current” or 
“previously” for at least one protease inhibitor was considered protease inhibitor 
treatment experienced (further referred to as TE; n = 515).  Indications of category 
“never” were rarely used. As a consequence, there was no explicit statement that a 
specific TE patient was never treated with any other protease inhibitor than those 
marked as “current” or “previously”. As another consequence, there were 
complications with assigning samples to the protease inhibitor treatment naïve 
category, so we compared the blood collection date for every sample with the FDA 
approval dates of protease inhibitors. In case the former date was prior to the latter 
date for a given sample and protease inhibitor, treatment status was switched to 
“never”. The group of protease inhibitor treatment naïve samples included those 
samples with the status “current” or “previously” for none of protease inhibitors 
(further referred to as TN, n = 825). 
 
5.1.2 Statistical analysis 
 
Data analysis was performed using R language [216]. Statistical 
associations were assessed using Fisher’s exact test with a significance level of 
0.95. Prevalence of Gag and protease mutations in the viral sequences of TE 
patients versus TN patients was assessed. We defined and analyzed these distinct 
types of mutations: Primary PI resistance mutations in protease; Secondary PI 
resistance mutations in protease; Other protease mutations; Treatment associated 
Gag mutations. Comparisons were performed for subtype B viruses (n = 890; of 
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those TE n = 369, TN n = 521). Processing and classification of our sequences are 
summarized in Figure 14. 
 
5.1.3 Pairwise associations between mutations 
 
Fisher’s exact test was used to evaluate possible statistical associations 
between amino acid mutations. We selected significance level of 0.95 as critical 
cutoff. Obtained associations were visualized in heat-map fashioned correlation 
graph. Only mutations and mutational pairs occurring in more than 1% of total TE 
samples were included. 
 
5.1.4 Construction of mutagenetic trees 
 
Implementation of mtreemix software by Beerenwinkel et al. [217, 218] in 
R language was performed by Bogojeska et al. [219]. Resulting Rtreemix package 
allows modeling multiple paths of ordered accumulation of genetic changes from 
cross-sectional data. Assuming mutations occurred are permanent, it estimates 
local maximum likelihood mutagenetic tree using a combination of graph-
theoretical method with an expectation-maximization approach. These models 
have been successfully used to scrutinize HIV resistance development 
characterized by ordered accumulation of resistance mutations in the viral genome 
under drug pressure [220]. 
To estimate stability of fit models we performed 1000 rounds of 
bootstrapping and selected tree branches by the number of bootstraps they were 
supported with. 
 
5.1.5 Learning Bayesian network 
 
We used Bayesian networks in order to model the role of mutations 
observed along with their interactions. R package pcalg [221, 222] implements this 
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probabilistic model describing statistical independencies between multiple 
variables [223]. We approached our dataset using two pairs of algorithms. FCI 
(Fast Causal Inference) algorithm [224, 225] paired to GBC (Generalized 
Backdoor Criterion) algorithm [226] were used to strictly approach our 
observational data with the assumption that it contains some hidden or selection 
variables. Alternative pair included PC (Peter-Clark) [225] and IDA (Intervention 
calculus when DAG is Absent) [227] algorithms with more relaxed assumption 
that our data contains no hidden and selection variable. Constructed models are 
visualized with directed acyclic graphs in which dependencies can be represented 
with edges. Applied algorithms extract the network capable of explaining a 
maximum of statistical correlations between the variables in the data using 
minimum edges. Binary representations of amino acid sequences labelled with a 
parameter for PI exposure were fed to the program.  
 
 
Figure 14. Processing and classification of the sequences obtained. TE – 
protease inhibitor treatment experienced, TN – protease inhibitor treatment naïve, 
stB – subtype B. 
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5.2 Experimental part - materials 
5.2.1 Chemicals 
   
CHEMICAL  SUPPLIER 
   
PCR   
dNTPs (dATP, dCTP, dGTP, dTTP), 10mM  Sigma 
PfuUltra II Fusion HS DNA Polymerase  Agilent 
PfuUltra II Reaction Buffer, 10x  Agilent 
   
Gel electrophoresis   
Agarose  Cambrex 
TBE buffer, 10x  Amresco 
Ethidium bromide solution (10mg/ml)  Sigma 
1kb DNA ladder (1µg/µL)   Invitrogen 
100bp DNA ladder (1µg/µL)  Invitrogen 
   
DNA isolation and purification   
NucleoSpin® Plasmid / Plasmid (NoLid)  Macherey-Nagel 
NucleoSpin® Gel and PCR Clean-up  Macherey-Nagel 
   
Bacterial Culture, Competent Cells Preparation   
Bacto Agar (dehydrated)  Becton-Dickinson 
Bacto Tryptone (dehydrated)  Becton-Dickinson 
Bacto Yeast Extract (dehydrated)  Becton-Dickinson 
NaCl  Fluka 
Ampicillin (sodium salt)   Sigma 
Glycerol (87%)   Fluka 
CaCl2 dihydrate    Fluka 
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One Shot® TOP10 cells  Invitrogen 
HB101 cells  Promega 
   
Cloning   
BamHI  New England Biolabs 
XmaI  New England Biolabs 
Hind III  New England Biolabs 
BssHII  New England Biolabs 
Digestion buffers, 10x  New England Biolabs 
Bovine Serum Albumin (BSA), 10x  New England Biolabs 
Alkaline Phosphatase, Calf Intestinal (CIP)  New England Biolabs 
Quick Ligation Kit  New England Biolabs 
   
Sequencing   
BigDye® Terminator v3.1 Cycle Sequencing   Applied Biosystems 
BigDye® v1.1/3.1 Sequencing Buffer (5X)  Applied Biosystems 
   
Cell culture   
DMEM High Glucose (4.5g/L) with Stable Glutamine  BioConcept 
RPMI 1640, with 25mM HEPES (w/o L-Glutamine)  BioConcept 
L-Glutamine, 200mM (100x), liquid  Gibco 
jetPRIME® transfection reagent  
Polyplus 
Transfection 
jetPRIME® buffer  
Polyplus 
Transfection 
Fetal Bovine Serum (Heat Inactivated)  Gibco 
Trypsine/EDTA (w/o Ca2+/Mg2+)  Gibco 
D-PBS (1x), liquid (w/o Ca2+/Mg2+)  Gibco 
Trypan Blue Stain, 0.4%   Gibco 
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Pen/Strep  BioConcept 
   
Virus Inactivation and Cells Fixation   
Formaldehyde (36.5%)  Fluka 
Glutaraldehyde (25%)  Fluka 
   
ONPG assay   
Buffer Z   NA 
Buffer H   NA 
o-Nitrophenyl-β-D-Galactopyranoside (ONPG)  Amresco 
β-Mercaptoethanol (100%)  Fluka 
   
Antiretrovirals   
Atazanavir  Bristol-Myers Squibb 
Darunavir  Tibotec 
Indinavir  Abbott Laboratories 
Lopinavir  Abbott Laboratories 
Nelfinavir  Abbott Laboratories 
Saquinavir  Abbott Laboratories 
Amprenavir  Abbott Laboratories 
Efavirenz  Abbott Laboratories 
T-20  Abbott Laboratories 
Dimethyl sulfoxide (DMSO)   Riedel-de Haën 
   
General chemicals   
Ethanol (100%)   Fluka 
Sodium hypochlorite (10%)  Fluka 
Dismozon  Bode Chemie 
 
  
47 
 
5.2.2 Cell lines 
  
CELL LINE DESCRIPTION SOURCE 
HeLa Human adherent transfection cell line 
Prof. Dr. 
Thomas 
Klimkait 
  
293T Human semi-adherent transfection cell line 
  
SxR5 
HeLa – derived reporter cell line. Contains 
integrated plasmid with an HIV-1 LTR driving 
bacterial LacZ gene. Expresses CD4 receptor as 
well as CXCR4 and CCR5 co-receptors. 
 
5.2.3 Plasmids 
 
PLASMID DESCRIPTION SOURCE 
pNL 4-3 
Provirus derived from NY5 (5’) and LAV (3’) 
HIV-1 isolates, cloned into pUC18 into the PvuII 
site (size: 14,877bp) [228] 
Dr. 
Malcolm 
Martin 
(NIH)  
   
pNL-NF 
pNL 4-3 truncated in the flanking regions (cut 
with NaeI and FspI) 
Prof. Dr. 
Thomas 
Klimkait 
   
pNotI5-BX 
Cloning cassette containing: BssHII, NotI/1141, 
BamHI/2424 and XmaI/2796 
Prof. Dr. 
Thomas 
Klimkait 
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All mutants of interest were generated using the pNL-NF scaffold by 
overlap-PCR. Then generated and properly prepared Gag-PR inserts were ligated 
into the accordingly prepared cloning cassette pNotI5-BX. 
The pNL-NF plasmid represents a shorter version of pNL4-3, the wild-type 
reference of an HIV-1 B subtype virus, in which the human flanking sequence had 
been reduced to a minimum. PNotI5-BX is a pNL-NF based cloning cassette for 
Gag and PR. The two restriction sites BssHII and XmaI of pNotI5-BX allowed the 
direct insertion of the mutated Gag-PR fragment. Since all plasmids contain as 
backbone the pUC18 plasmid, they can readily be amplified in E. coli and confer 
ampicillin resistance upon transformation. 
 
  
49 
 
5.2.4 Mutants 
 
Mutations of interest were identified using analytical approach and introduced into standardized pNL-NF backbone using 
the overlap mutagenesis method. Amino acid substitutions were codon-optimized. 
Protein Mutation Wild-type Substitution 
Nucleotide  
position 
Nucleotide change 
Number of  
nucleotide 
changes  
Human  
codon 
usage 
Gag T427D T (Threonine) D (Aspartic Acid) 2068-2070 ACT->GAT 2 21.8 
Gag R429I R (Arginine) I (Isoleucine) 2074-2076 AGA->ATC 2 20.8 
Gag A431V A (Alanine) V (Valine) 2080-2082 GCT->GTG 2 28.1 
Gag I437V I (Isoleucine) V (Valine) 2098-2100 ATC->GTG 2 28.1 
Gag Y441Q H (Histidine) Q (Glutamine) 2110-2112 CAC->CAG 1 34.2 
Gag L449P L (Leucine) P (Proline) 2134-2136 CTT->CCT 1 17.5 
Gag L449V L (Leucine) V (Valine) 2134-2136 CTT->GTG 2 28.1 
Gag S451H S (Serine) H (Histidine) 2140-2142 AGC->CAC 2 15.1 
Gag S451N S (Serine) N (Asparagine) 2140-2142 AGC->AAC 2 19.1 
Gag R452S R (Arginine) S (Serine) 2143-2145 AGA->AGC 1 19.5 
Gag P453L P (Proline) L (Leucine) 2146-2148 CCA->CTG 2 39.6 
PR I47V I (Isoleucine) V (Valine) 2391-2393 ATA->GTG 2 28.1 
PR I54V I (Isoleucine) V (Valine) 2412-2414 ATC->GTG 2 28.1 
PR V82A V (Valine) A (Alanine) 2496-2498 GTC->GCC 1 27.7 
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5.2.5 Primers 
 
All primers were named according to their 5’ end position preceded by an “F” for forward or an “R” for reverse primers. 
This notation allows calculating directly the size of a fragment from the name of primers. 
 
Name Purpose Sequence 5'-3' Basic Tm, °C 
 
“Border” primers for site-directed mutagenesis 
F-707L BssHII RS TGAAGCGCGCACRGCAAGAGGCGAG 64.2-65.9 
R-2598 XmaI RS CCATCCCGGGCTTTAATTTTACTGG 57.7 
 
Mutagenesis primers 
F-2061-T427D T427D AGA TTG TGA TGA GAG ACA GGC TA 53.5 
R-2083-T427D T427D TAG CCT GTC TCT CAT CAC AAT CT 53.5 
F-2062-R429I R429I GAT TGT ACT GAG ATC CAG GCT AAT 54 
R-2085-R429I R429I ATT AGC CTG GAT CTC AGT ACA ATC 54 
F-2074 A431V AGACAGGTGAATTTTTTAGGGAAGA 52.8 
R-2094 A431V CCCTAAAAAATTCACCTGTCTCTCAGTACAA 59.1 
F-2084M I437V ATTTTTTAGGGAAGGTGTGGCCTTCC 58 
R-2105 I437V GGCCACACCTTCCCTAAAAAATTAGCCTGT 61.6 
F-2099-Y441Q Y441Q TC TGG CCT TCC CAG AAG GGA A 56.3 
R-2119-Y441Q Y441Q TTC CCT TCT GGG AAG GCC AGA 56.3 
F-2128 L449P AATTTTCCTCAGAGCAGACCAGAGC 57.7 
R-2142 L449P GCTCTGAGGAAAATTCCCTGGCCTT 59.3 
F-2128-L449V L449V AATTTTGTGCAGAGCAGACCAGAGC 57.7 
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R-2142-L449V L449V GCTCTGCACAAAATTCCCTGGCCTT 59.3 
F-2131-S451H S451H TTT CTT CAG CAC AGA CCA GAG 52.4 
R-2151-S451H S451H CTC TGG TCT GTG CTG AAG AAA 52.4 
F-2131-S451N S451N TTT CTT CAG AAC AGA CCA GAG CCA 55.7 
R-2154-S451N S451N TGG CTC TGG TCT GTT CTG AAG AAA 55.7 
F-2137-R452S R452S CAGAGCAGCCCAGAGCCAACAGCCC 65.9 
R-2158-R452S R452S CTGTTGGCTCTGGGCTGCTCTGAAGAAAA 62.9 
F-2140 P453L AGC AGA CTG GAG CCA ACA GCC C 64.2 (60.4) 
R-2158 P453L C TGT TGG CTC CAG TCT GCT CTG AAG AAA A 57.7 (61.5) 
F-2383-I47V I47V CAA AAA TGG TGG GGG GAA TTG GA 55.3 
R-2405-I47V I47V TCC AAT TCC CCC CAC CAT TTT TG 55.3 
F-2404 I54V GAGGTTTTGTGAAAGTAAGACAGTATGATC 57.5 
R-2424 I54V GTCTTACTTTCACAAAACCTCCAATTCCCC 60.3 
F-2483 V82A AGGACCTACACCTGCCAACATAATTG 58 
R-2504 V82A TATGTTGGCAGGTGTAGGTCCTACTAATAC 60.3 
 
Sequencing primers 
F-620 BssHII region GGA AAA TCT CTA GCA GTG GCG 54.4 
F-1400 Gag region CCA TCA ATG AGG AAG CTG CAG 54.4 
F-1985 Gag-Pol region TTA AGT GTT TCA AYT GTG GCA ARG AAG G 55.5-58.5 
F-2084 XmaI region ATT TTT TAG GGA AGA TCT GGC 48.5 
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5.3 Experimental part – methods 
5.3.1 Overlap PCR 
 
PCR-reactions were typically performed in a 50 µL volume. Primer stocks 
were stored at -20C at a concentration of 100 µM. Working primer solutions were 
prepared at 10 µM. For each reaction 2µL of each primer are used, corresponding 
to 20pmol (final concentration of 400nM). The amount of DNA template ranged 
from 10 to 50 ng. Additionally 1.25 µL of 10mM dNTPs, 5 µL of 10x polymerase 
reaction buffer and 1 µL of polymerase were added. The volume then was filled up 
to 50 µL with autoclaved mQ water. 
A standard amplification cycle is set up as it follows (in total 30 cycles): 
 
Step Time Temperature, C  
Denaturation 2’ 98  
Denaturation 20’’ 98 
30 cycles Annealing 20’’ Primer Tm – 5°C 
Elongation 30’’-60’’ 72 
Elongation 3’’ 72  
Pause - 4  
 
The annealing temperature was selected according to the primer pair used. 
The extension time was adjusted according to the fragment amplified. Reactions 
were set up on ice to prevent unspecific primer annealing to the template. 
The first step of overlap PCR included to parallel reactions on the same 
template in different tubes (Figure 15). One reaction used forward flanking and 
reverse mutagenic primer, another – forward mutagenic and reverse flanking 
primer. Mutagenic primers were designed so that they overlap on at least half of 
their annealing site length and introduce the same nucleotide changes from the 
selected template. 
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The second step included a single PCR reaction with purified products of 
the first step as a template and flanking primers (Figure 16). 
 
 
 
Figure 15. First step of the mutagenesis by overlap extension PCR. Primer 
2 and Primer 3 – are flanking primers. Mutated primer 1a and mutated primer 1b – 
are the primers introducing desired mutations. Black bold mark indicated 
nucleotide difference introduced. Blue and red colors indicate template target 
regions for the two independent reactions at this stage. Green lines indicate 
products of the reaction while green dots visualize elongation of the primer on a 
given template. Illustration by Alessio Cremonesi [229].   
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Figure 16. Second step of the mutagenesis by overlap extension PCR. 
Black bold marks indicate the nucleotide difference introduced. Green lines 
indicate products of the reaction while green dots visualize elongation of the 
primer on a given template. Illustration by Alessio Cremonesi [229]. 
 
5.3.2 Bacterial culture 
 
LB medium with ampicillin: 5g NaCl, 10g Bacto Tryptone, and 7g Bacto 
Yeast Extract are dissolved in 1L milliQ H2O and autoclaved. When the solution is 
at room temperature, 1mL ampicillin (200mg/mL) is added: final antibiotic 
concentration is 200µg/mL. 
LB agar plates with ampicillin: 2.5g NaCl, 5g Bacto Tryptone, 3.5g Bacto 
Yeast Extract, and 6g Bacto Agar are dissolved in 0.5L milliQ H2O and 
autoclaved. After cooling down the solution, 0.5mL ampicillin (200mg/mL) are 
added: final antibiotic concentration is 200µg/mL. Approximately 20mL medium 
are poured in each Petri dish. 
 
5.3.3 Preparation of competent bacterial cells 
 
Both HB101 and One Shot® TOP10 competent cells are AmpS and contain 
a recA mutation, which prevents undesirable recombination events. In addition, 
One Shot® TOP10 bacteria have an endA mutation that prevents carry-over of 
nucleases. Both cells are chemically competent. 
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Cells are plated on LB agar w/o ampicillin and incubated over night at 
37°C. The next day one single colony is inoculated in 5mL LB medium and 
incubated overnight on a shaker. From the overnight culture, 5mL are transferred 
into 1L LB medium and let grown till OD260 of 0.2-0.5.Afterwards cells are 
transferred in 50mL tubes and put immediately on ice for 10’. Centrifugation is 
done at 4°C for 20’ (2,500rpm). Supernatant is removed and cells are resuspended 
in 25mL ice cold 100mM CaCl2 and centrifuged under the same conditions as 
before. After resuspending cells in 10mL ice cold 100mM CaCl2, they are put on 
ice for 30’ and then centrifuged. Following supernatant removal, cells are well 
mixed in 50mL ice cold 100mM CaCl2 with 10% glycerol and aliquoted into PCR 
tubes, which are stored at -80°C. Bacteria are plated on LB agar with and w/o 
ampicillin to check for contaminations and concentration; moreover a 
transformation test with 10ng pNL-NF is done to check their transformation 
efficiency. 
 
5.3.4 Plasmid DNA purification 
 
DNA plasmid extraction is performed with Macherey-Nagel kit according 
to the enclosed protocol. For a miniprep, the starting amount of LB culture is 4 
mL, for a midiprep 100mL, and for a maxiprep 250mL. The DNA content is 
quantified by UV spectrometry at 260nm using NanoDrop® ND-1000. Typically 
A260/A280 and A260/A230 ratios (for DNA 1.8 and 1.8-2.2, respectively) are 
monitored to estimate DNA purity. 
 
5.3.5 Gel extraction 
 
PCR products and prepared vector fragments (backbones and inserts) are 
extracted from agarose gel with Macherey-Nagel kit according to the enclosed 
protocol. The DNA concentration is normally not measured by UV spectrometry at 
260nm, since the measurement is not very reproducible, due to low yield. At low 
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concentrations this measurement has a qualitative rather than quantitative 
character. 
 
5.3.6 Vector preparation 
 
Typically 2-4 µg of DNA were digested using 1-5 overdigestion as in 20 or 
50 µl reaction as recommended by the enzyme manuals. High enzyme and glycerol 
(>5% v/v) concentrations can cause star activity and were therefore avoided. In 
case enzymes had different optimal temperatures they were added to the reaction 
mix and incubated sequentially for an hour each. Afterwards 1 µl of CIP 
phosphatase is added to remove 5´ phosphates from the cut plasmid, which 
prevents vector re-circularization. The reaction is incubated for 30’ at 37°C. Then 
the sample was run in agarose gel and the band of expected size was excised and 
gel-purified. 
 
5.3.7 Cloning and transformation 
 
All inserts were digested for 1 hour with the appropriate combination of 
restriction enzymes at optimal conditions according to the enclosed manuals. The 
enzymes were heat-inactivated. The theoretical molar ratio between insert and 
vector should be approximately 3:1. Nevertheless, better results were obtained with 
higher ratios. In general 50-70ng of vector were used together with 2µL insert at 5-
10ng/µL. An equivalent volume of 2x Quick ligation buffer was added and the 
reaction is incubated at 25°C for 20’. A negative control containing the vector 
alone is always performed to estimate the background of vector self-ligation.  
Afterwards, 100µL of fresh thawed competent cells (either HB101 or One 
Shot® TOP10) were added to the ligation mix and the tubes are incubated on ice 
for 30’ (bacteria were resuspended only few times to avoid mechanical lysis). 
Bacteria were heat-shocked at 42°C for 1’’ and put back on ice for 10’. Depending 
on the aim of the experiment, bacteria are either put in liquid LB medium or plated 
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on LB agar. On one side, if a mixture of different inserts is cloned and has to be 
preserved, bacteria were incubated in 4mL liquid LB medium with ampicillin and 
incubated overnight at 37°C on a rocking platform. On the other side, if single 
clones had to be isolated after heat-shock, bacteria were plated on LB agar plates 
containing ampicillin and incubated overnight at 37°C. The next day colonies were 
picked up and grown in liquid culture. 
 
5.3.8 Restriction digestion 
 
Usually 1µL of plasmid DNA preparation (approximately 300ng/µL) was 
digested with 0.3U of each enzyme, 1µL of appropriate buffer 10x, 1µL of BSA 
10x, and H2O up to total volume of 20µL. The reactions were incubated at 
appropriate temperatures for 1 hour. Subsequently samples were run on agarose gel 
and obtained restrictions patterns were compared to the ones expected. 
 
5.3.9 DNA sequencing 
 
Sequencing was performed in-house using Applied Biosystems 3130 
Genetic Analyzer and the corresponding sequencing kit. Sequencing primers were 
purified through HPLC by the manufacturer. Sequencing reaction mix included: 
 
5x Sequencing Buffer 3.0 µL 
1mM primer 3.0 µL 
5x Big Dye Terminator v3.1 1.5 µL 
Sample 200-600 ng, typically 1.0 µL 
mQ H2O Up to 20 µL 
 
The PCR cycling is set up as follows: 
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Step Time Temperature, C  
Denaturation 5’ 95  
Denaturation 30’’ 95 
40 cycles Annealing 10’’ 55 
Elongation 4’ 60 
Pause - 4  
 
For subsequent purification 96 well filtration plates were used. They were 
filled with Sephadex and 300 µL mQ H2O per well. Sephadex was let to swell for 
three hours at room temperature. Afterwards excess water was removed by 
centrifugation, and samples loaded on the filtration plate. During subsequent 
centrifugation samples were collected in 96 well sequencing plate and loaded to 
the sequencer.  
 
5.3.10 Cell culture 
 
Hela and SxR5 are adherent cells and 293T are semi-adherent cells. They 
were grown in DMEM High Glucose (4.5g/L). All cells were split three times a 
week. Before splitting, cells were examined by microscopy to check for confluence 
and possible contamination. For passaging medium was removed and cells were 
washed with PBS w/o Ca
2+
 and Mg
2+
, and trypsinized with trypsin-EDTA. After 
incubation at 37C for 5’ cells normally detached, were resuspended in DMEM 
and counted. Appropriate numbers of cells were resuspended in a flask with fresh 
medium. The cells were maintained until passage 20, before a new aliquot was 
thawed. 
All three cell lines are stored in 1mL aliquots at -196°C (liquid nitrogen). 
They are thawed gently but at the same time quickly since cells are in a freezing 
solution containing 10% DMSO. Freshly thawed cells are added to culture 
medium, centrifuged, resuspended and finally incubated at 37C and 7% CO2 in 
fresh medium. 
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5.3.11 Preparation of antiretrovirals 
  
Drug stocks were prepared from pills and then were diluted in two formats, 
either 6 or 10 concentrations depending on the experiment. Drugs were diluted 
according to their solubility in polar solvents. Moreover, each drug has its own 
range of concentrations depending on the IC50 value, in order to accurately 
extrapolate the inhibition curve. 
 
5.3.12 deCIPhR 
  
The HIV drug resistance phenotyping assay applied in the study was the 
deCIPhR system (dual enhancement of cell infection to phenotype resistance) [230, 
231] as available through Th. Klimkait. It represents a proprietary assay of 
InPheno AG, permitting viral replication during assessment. Briefly (Figure 17), 
each proviral DNA is transfected into a human epitheloid cell line (HeLa or 293T) 
using a transfecting agent (jetPrime) leading to production of fully infectious HIV-
1 particles. Cell-to-cell spread and replication of recombinant viruses is allowed 
for a period of four days in the absence or presence of specific drugs by co-culture 
with a reporter cell line (SxR5) expressing CD4 and both chemokine receptors 
CXCR4 and CCR5. In addition, the genome of this cell line contains the HIV-1 
Long terminal repeat (LTR) fused upstream of the bacterial reporter gene LacZ 
coding for β-Galactosidase. Therefore in these cells, the activity of β -
Galactosidase is proportional to the extent of viral replication. In the final step of 
the process, the cells are lysed to incubation with a chromogenic substrate for β -
Galactosidase, ortho-nitrophenyl-galactopyranoside (ONPG). 
In a sterile 2 mL tube, 1 μg of plasmid DNA (e.g., pNL4-3 or derivatives) 
are added to 100 μL of jetPRIME® buffer and mix by vortexing. The 2μL of 
jetPRIME® reagent are added on top and vortexing is performed. The solution is 
incubated at room temperature for 10’. A master mix is prepared for several 
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transfections. HeLa or 293T cells are harvested by trypsinization, counted, and an 
aliquot of 0.25 x106 cells in 500 μL of complete DMEM is set aside for each 
transfection. At the end of the incubation period, the cell aliquot is added to the 
transfection mix and the 2mL tube is returned to a 37°C cell incubator. 
In a 96-well microtiter plate (96-w MTP) 10 μL of a 20x dilution of the test 
drug(s) (in cDMEM/DMSO) are added. In plate format positive and negative 
controls i.e., wells containing a reference inhibitor (e.g., 300 nM Efavirenz = 0% 
readout) or diluent (= 100% readout), are always included. SxR5 cells are 
harvested and counted (BSL2 cell culture lab). Then transfected cells are mixed 
with 1.1x10
6
 SxR5 cells in 42 mL of fresh medium. After that 190 μL of the mix 
are distributed to each well of two 96-w MTP with drug dilutions. Plates are 
returned into the incubator for 4 days (BSL3). 
Then β-galactosidase development is performed: 96-well tissue culture 
plates are removed out of cell culture incubator and culture media is aspirated. 
Then 10 μL of Glo Lysis Buffer is added per well. Plates are cleaned with bleach 
from outside and on the inner surface of the lid and transferred to the main lab. 
Eighty μL of ONPG solution are dispensed into each well. The plates are read 
using reader set at 405nm wavelength. The optimal maximal absorbance is at least 
0.4 to 0.8. The data obtained is analyzed using an Excel spreadsheet template with 
XLFit as add-in. In this template, raw data (absorbance at 405 nm) are converted 
into percent inhibition using the following formula: InhX = 100 – (((ReadoutX – 
Readout0%) / (Readout100% - Readout0%)) x 100), where: InhX – percent of 
inhibition; ReadoutX - absorbance of well containing substance ‘X’; Readout0% - 
absorbance average of 6 wells containing cells incubated in reference inhibitor 
(e.g., 300 nM Efavirenz); Readout100% - absorbance average of 6 wells 
containing cells incubated in diluent. Averages of all triplicates are then computed 
and XLFit determines EC50 and generates a graph plotting percent of inhibition as 
a function of concentration. 
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Figure 17. Principle of dual-enhancement of Cell-Infection for 
Phenotyping Resistance (deCIPhR). Illustration was kindly provided by Th. 
Klimkait [230, 231]. 
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6 RESULTS 
6.1 Prevalence of protease inhibitor resistance in protease 
 
In order to validate our analytical approach we examined in a first step the 
prevalence of well-established PI resistance mutations for therapy-experienced 
(TE) and therapy-naïve (TN) samples. Among the collection of TE viruses 24.9% 
carried any kind of primary resistance mutations in the protease gene. This is in a 
good agreement with published data from Germany, reporting 30% (473 / 1586; 
p>0.05) [232] of resistance-associated changes. Eight primary resistance mutations 
were found to be significantly overrepresented in the TE over TN group: D30N, 
V32I, M46L/I, I54V, V82A, I84V, and L90M. In line with previous reports [233, 
234], the frequency of none of these primary PI resistance mutations individually 
exceeded 4% in the TN group. 
Also nine secondary PI resistance mutations in protease were found to 
significantly associate with the TE group of samples: L10F/I, L33F, Q58E, L63P, 
A71V/I, 73S, and N88D. For most of the secondary PI resistance mutations the 
frequency did not exceed 10% in TN group. Only the known polymorphism L63P 
occurred, as seen before, in 51.3% [104, 190, 235, 236], and the alterations A71V 
and L10I were identified in 12.9% and 10.7% of TN samples. Frequencies of these 
two mutations among TN patients of the SHCS have been reported to be 8.9% (108 
/ 1208; p>0.05) and 9.7% (118 / 1281; p<0.05)  [236]. 
 
6.2 Correlation between PI exposure and Gag mutations 
 
We assessed the prevalence of Gag mutations that have previously been 
reported to associate with PI-exposure or -resistance. Among the TE samples in 
our study 84.2% carried at least one of 48 known Gag mutations. Verheyen et al. 
reported the rate of known Gag mutations to be as high as 65.3% [202], but 
considered solely cleavage site mutations at p7/p1 and p1/p6. 
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Also other correlates of PI treatment with Gag changes were verified in the 
Swiss dataset: A431V (8.2%; OR=3.4), I437V (6.5%; OR=3.2), P453L (13.1%; 
OR=2.3), I479I (64.4%; OR=1.34). However, only for mutations A431V, I437V 
and P453L a phenotypic proof of PI resistance by in vitro mutagenesis has been 
published [10, 192, 237]. Among all analyzed TE sequences in our data set 17.9% 
carried at least one of the latter three mutations compared to the significantly lower 
number of 8.3% of the TN samples in the set. These figures are overall in 
agreement with the 19.1% (43 / 225; p>0.05) for TE and 12.1% for TN samples 
reported by Verheyen et al., [202] (33 / 275; p>0.05). 
When assessing the association of those mutations with primary resistances 
in protease, only mutation A431V was found to correlate in the vast majority of 
cases (93.8%). Mutations P453L and I437V occurred along with primary PI 
resistances in 60.5% and 42.9%, respectively, and only 26.4% of those samples 
with I479I carried any known protease resistance mutation.  
Like secondary PI resistance mutations in protease, several Gag alterations 
have been described in phenotypic in vitro experiments as being capable of 
compensating for fitness loss and of cooperatively decreasing PI susceptibility 
when they occurred in combination with primary PI resistance mutations [10-13]. 
We therefore assessed novel gag mutations emerging during PI exposure: 
Mutations T427D/N (10.4% vs 3.9% in TN; OR=2.9) and E467V/K (3.6% vs 0.8% 
in TN; OR=4.8) associated specifically with PI treatment. In addition, a link to the 
exposure to certain drugs could be demonstrated for these alterations: T427D/N to 
LPV (13.2%; OR=3.1), E467K to NFV (3.8%; OR=3.5), Q474H to DRV (5%; 
OR=3.5), and Y484P to DRV (5%; OR=5.3). With respect to combined Gag-
mutations the occurrence of mutation Q474H correlated with the emergence of 
T427N (13.3%; OR=24.4) in our dataset. 
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6.3 Gag alterations in p2 and p7 
 
For a subset of samples from Basel the analyses yielded longer gag 
sequences, which cover also the p24/p2 cleavage site. Among these TE samples 
two novel alterations were identified to be of potential relevance: A360S/P (7% = 
6/86 vs 1.2% = 3/255; OR=6.3) and Q369L (8.1% = 7/86 vs 1.6% = 4/255; 
OR=5.5). Additionally, we found Q369L to be associated with other, established 
correlates of PI exposure: K418R (42.9%; OR=5.8), I437V (28.6%; OR=10.9) and 
P453T (42.9%: OR=15.0). 
 
6.4 PI usage at the study centres 
 
In the group of TE samples the respective frequencies of certain PIs were 
assessed. Three compounds were significantly more often applied in the Basel 
center (BS): NFV (60% vs 28.8% in ZH; OR=3.7), SQV (35.1% vs 12.5%; 
OR=3.8), IDV (54.1% vs 23.9%; OR=3.7). In contrast, Zurich (ZH) patients had 
been significantly more often exposed to ATV (36.4% vs 23.2% in BS; OR=0.5) 
and DRV (39.2% vs 8.3%; OR<0.1). This significant difference in the use of 
certain PI strongly hints differences in the choice of treatment regimens between 
the two centers, but it is likely that this also reflects differences in the average year 
of sampling since ATV and particularly DRV reflect more recent drugs than IDV 
or SQV. 
 
6.5 Pairwise association of Gag and protease mutations in the group of TE 
sequences 
 
In the TE sample group we observed links between 11 amino acid positions 
in Gag C-terminal region and 18 – in PR (Figure 18). In total we observed 188 
associations between certain amino acid substitutions. And not surprisingly, the 
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most interconnected were residues in PR which resulted in the hottest region on the 
correlation heat map (Figure 19). 
An absolute majority of protease resistances exhibited strong well-
described positive interconnections with other alterations in protease. And even 
among other primary resistances L90M, M46I, V82A and I54V stood out with 24, 
20, 19 and 18 observed significant links correspondingly. 
The secondary PI resistance mutations in protease A71V and L33F were 
the most interconnected in their class with 19 significant associations for each of 
them. While most of their links were confounded with protease region, key Gag 
resistance mutations P453L and A431V were their only correlates in Gag.  
Located at the p7/p1 and p1/p6 cleavage sites, these two mutations were the 
most interconnected of all Gag alterations with 18 significant correlations for each. 
Polymorphic L449P had 3 connections with mutations at the same p1/p6 cleavage 
site: S451G, P453T and P453L. I479I (previously reported to be PI-selected [203]) 
had as the only association the mutation of E468G. 
Novel correlates of PI exposure observed were almost not interconnected. 
Their links were limited exclusively with other alterations in Gag. T427D/N was 
linked to E467V/K, Q474H and Y484P. For E467V/K we report association with 
T427D/N, S451G and P453L. Associated together, both Q474H and Y484P were 
linked to T427D/N and S451N. 
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Figure 18. Arch diagram of covariation between Gag and protease. The 
line between two nodes indicates a covariation of corresponding residues. Node 
sizes are proportional to the degree of interconnection of a given residue. Red color 
indicates positions at which primary resistance mutations in protease have been 
described; yellow – secondary resistance mutations in protease; green – known 
Gag resistance- or treatment-associated mutations; black – newly identified 
treatment-associated mutations in Gag. 
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Figure 19. Heat map representing pairwise correlations in the Gag-PR 
region considered. Alterations were ordered according to their positions. Red 
labels indicate primary PI resistance mutations in protease; orange labels – 
secondary PI resistance mutations in protease; green labels – established correlates 
of PI exposure in Gag; black labels – novel correlates of PI exposure in Gag. Only 
significant associations were presented with colored squares. Alterations with no 
significant correlations were excluded. Odds ratios (OR) were plotted in 
logarithmic scale. 
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6.6 Patterns and predicted order of accumulation of mutations 
 
We investigated clusters of mutations occurring among TE samples in a 
more detailed way. Multiple paths of ordered accumulation of genetic changes 
were modelled using random tree mixture approach. Those with the best bootstrap 
support and topology well corresponding to the observed pairwise associations 
were visualized as mutagenetic trees presented in Figure 20 and Figure 21. 
The first model (Figure 20) explained up to 68% of observed sequence 
variants. Up to 38% of samples corresponded to the unordered model of 
accumulation of Gag and protease alterations or to the models that could not be 
robustly identified from our dataset. Second tree (Figure 21) was estimated to 
cover up to 56% of observed sequence variability leaving up to 50% for unordered 
or not observed mutational pathways.  
Newly identified correlates of PI exposure in Gag were incorporated by the 
algorithm into the mutational pathways along with primary and secondary PI 
resistance mutations in protease and established treatment-associated alterations in 
Gag. Both trees obtained demonstrated the tendency of resistance-related 
mutations in protease to prime the occurrence of Gag alterations. 
 
6.7 Bayesian networks analysis 
 
We approached our data with two different pairs of algorithms to infer 
Bayesian networks. One, stricter, suggested our data contained hidden and 
selection variables while another, more relaxed, suggested the opposite. 
Nevertheless, an inferred background association skeleton was identical in both 
cases. Fourteen identified edges just supported observed pairwise associations 
among primary resistance mutations in protease (Figure 19) but did not provide 
any additional data on top of it.   
We expected treatment exposure parameter to be directly linked to and 
identified as the cause for the presence of primary PI resistance mutations in 
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protease. Secondary PI resistance mutations in protease and established Gag 
resistances were expected to link to the PI exposure through the primary resistance 
mutations in protease.  In contrast to our expectations, we could not observe direct 
causal links between the PI exposure and primary resistance mutations in protease. 
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Figure 20. First mutagenetic tree illustrating mutational pathways for Gag 
and PR mutations observed in the dataset. Green boxes represent known treatment- 
and resistance-associated mutations in Gag, black – novel treatment-associated 
mutations in Gag, red and yellow – primary and secondary resistance mutations in 
protease correspondingly. Arrows indicate order of appearance. Simultaneous 
evolution along different pathways is possible, but a mutation can only occur in a 
sample, if all its predecessors (as seen from the root) were also present. First two 
numbers next to an arrow represent 95% confidence interval for the conditional 
probability of occurrence of the next respective genetic event. Third number 
indicates bootstrap support of a given element. Only tree structure supported by at 
least 500 out of 1000 bootstraps was taken into account. Dashed line indicates a 
branch with no support from the analysis of pairwise associations. From 62% to 
68% of samples fit in the ordered accumulation model while the rest (32% - 38%) 
can be explained by an unordered appearance or other, not observed, pathways. 
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Figure 21. Second mutagenetic tree illustrating mutational pathways for 
Gag and PR mutations observed in the dataset. Green boxes represent known 
treatment- and resistance-associated mutations in Gag, black – novel treatment-
associated mutations in Gag, red and yellow – primary and secondary resistance 
mutations in protease correspondingly. Arrows indicate order of appearance. 
Simultaneous evolution along different pathways is possible, but a mutation can 
only occur in a sample, if all its predecessors (as seen from the root) were also 
present. First two numbers next to an arrow represent 95% confidence interval for 
the conditional probability of occurrence of the next respective genetic event. 
Third number indicates bootstrap support of a given element. Only tree structure 
supported by at least 500 out of 1000 bootstraps was taken into account. Dashed 
line indicates a branch with the bootstrap support below selected cutoff with no 
support from the analysis of pairwise associations. From 50% to 56% of samples 
fit in the ordered accumulation model while the rest (44% - 50%) can be explained 
by an unordered appearance or other, not observed, pathways. 
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6.8  Selected phenotypes 
 
We developed, verified by sequencing and phenotypically tested in 
duplicates several single-point mutants, double-mutants and broader combinations. 
Mutations in Gag A431V, I437V, L449V, L449P, S451N, S451H, R452S, P453L 
and mutations in PR I47V, I54V, V82A were selected as known resistance 
associated alterations. Mutation T427D was statistically identified to be associated 
to PI treatment. And alterations R429I and Y441Q showed tendency for 
overrepresentation in TE group. 
In our experiments none of single mutants demonstrated any significant 
difference in PI susceptibility; however, we observed a decrease of viral fitness 
(Table 3). For none of emerging double mutants of interest an increase in drug 
resistance could be shown but rather a further fitness decrease: L449P-P453L – 
81%, S451N-I47V – 59%, T427D-I54V – 37%. The first pair observed in our 
dataset had been discussed by Verheyn et al. [202]. The second and third pairs 
demonstrated association tendency in our dataset. Additionally, covariation of 
S451N and I47V was also supported by the structural proximity and presence of 
electrostatic contact between them (Figure 22). 
Though tested mutations accumulated in PI treated sample group they did 
not confer any detectable resistance but rather decreased fitness. Our suggestion 
was that this might be due to the absence of necessary background alterations 
which might reveal the effects and functionality of selected mutations. Therefore 
we analyzed PR mutant L10I-M46I-I54V-A71V-V82A developed and 
characterized by Alessio Cremonesi as LPV (fold change IC50 2.4) and IDV (fold 
change 2.5) resistant and unfit [229] versus its Gag T427D, A431V, S451N and 
R452S derivatives. R452S has been described as potential Gag resistance and is 
particularly interesting due to its association with DRV and structural effects [238-
240]. Every clone demonstrated expected LPV and IDV resistance (Figure 23), 
susceptibility of other PI tested were not affected. Mutant PR L10I-M46I-I54V-
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A71V-V82A was 46% fit while addition of T427D, S451N or R452S increased the 
fitness up to 72-82%. In contrast, A431V decreased fitness down to 23%. 
 
Table 3. Fitness summary on single mutants that showed no resistance in 
phenotyping tests. 
Mutant 
Fitness compared 
 to pNL-NF, % 
 Mutant 
Fitness compared 
 to pNL-NF, % 
Gag_T427D 60  Gag_S451N 86 
Gag_R429I 47  Gag_S451H 77 
Gag_A431V 52  Gag_R452S 100 
Gag_I437V 57  Gag_P453L 75 
Gag_Y441Q 91  PR_I47V 75 
Gag_L449V 48  PR_I54V 90 
Gag_L449P 60  PR_V82A 25 
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Figure 22. Structural aspect of the interaction between residues 47 in PR and 451 in Gag (in purple). HIV-1 protease 
dimer (cartoon representation) with a decapeptide of its natural substrate p1/p6 Gag (stick representation). PDB ID: 1MT9. 
Flexible PR flaps are in yellow. Yellow dotted lines represent electrostatic contacts. When residue PR 47 has been mutated to 
obtain resistance electrostatic contact with residue Gag 451 and therefore optimal substrate accommodation in the PR substrate 
binding cleft might be lost. But when residue Gag 451 mutates accordingly electrostatic contact is restored. Therefore processing 
efficiency of the cleavage site is restored as well. 
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Figure 23. Phenotypes of the mutants with resistant PR in combination 
with Gag alterations. On the graphs percent of inhibition is represented with 
vertical axis and drug concentration in nM – with horizontal axis. Blue line – 
mutant, red line – pNL-NF reference.   
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7 DISCUSSION 
7.1 Validity of the chosen analytical approach 
 
This study is the first in the SHCS to systematically investigate the possible 
role of HIV-1 Gag mutations during PI treatment and for the emergence of viral 
drug resistance. The pilot steps of our analysis validated the analytical approach 
selected as the observed rates of primary and secondary resistances in the viral 
protease matched with previously published data well. The only slight difference 
was observed for secondary resistances A71V and L10I, which, based on previous 
data, were more prevalent than expected in TN samples in the SHCS data set. 
These two natural polymorphisms have not been attributed to failures on certain 
protease inhibitors [236] but were rather associated with unspecific cooperative 
decrease of PI susceptibility in vitro [104, 190]. So the difference is rather 
explained by reported natural geographical variability in prevalence of mutations 
and by sampling than peculiarities of treatment regimens [104, 190, 241, 242].  
These results confirm the validity of the statistical methods used in this study. 
 
7.2 Frequency of established Gag resistance mutations in the SHCS 
 
The frequencies of resistance-relevant known Gag mutations in the TE set 
of SHCS samples were in a good agreement with a report by Malet et al. [212], 
stating that at the variable positions at the p2/NC cleavage site alone 91% of PI-
exposed subtype B viruses exhibited at least one mutation. That supports our 
observations being true tendencies rather than method of region-specific artifacts. 
The occurrence of mutations I437V, P453L and I479I among the TE samples in 
the absence of accompanying primary protease mutations could indicate several 
mechanistic roles: They could either have an independent role in resistance or they 
might prime as initial steps mutations in PR or they could cooperate with 
secondary protease mutations. Of interest, P453L has been described up to here to 
confer resistance only when primary protease mutations in protease had emerged 
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[192]. And for I479I no phenotypic proof in a standardized background is 
available. This leaves I437V to as the most likely candidate to contribute to the 
failure of PI-containing regimens in the absence of primary resistances. In a 
standardized in vitro background it decreased the susceptibilities of LPV, TPV, 
ATV, and APV [10]. In 17.9% of all TE samples the Gag region carried mutations 
capable of decreasing PI susceptibility alone or in combination with PR 
resistances. Yet, the Gag region is not taken into account by routine genotyping. 
Therefore the overall level of PI resistance might be underestimated. 
 
7.3 Beyond established Gag resistances 
 
Most of the currently known mutations in Gag that have been associated 
with PI resistance reside in or near the p7/p1 and p1/p6 cleavage sites. Our study 
set out to complement this information by including the entire C-terminal region of 
Gag available from our dataset. Several mutations were newly associated with PI 
exposure. They were mainly located at functionally critical points of the Gag 
polyprotein. Both positions A360 and Q369 are well conserved among M-group 
isolates of HIV-1. Alterations at position 360 affect p24/p2 cleavage and have been 
reported to influence virion assembly and release [243]. Residue 369 belongs to the 
bevirimat binding sequence and is required for proper virion formation and 
maturation in vitro, a step that is dependent on the conformation of p2 (SP1) [94]. 
The folding of this short spacer peptide is likely to be strongly affected by the 
observed substitution exchanging the hydrophilic glutamine with the rather 
hydrophobic leucine. Furthermore, the association of Q369L with other known 
resistance-related alterations in Gag such as K418R, I437V, and P453T, as 
observed here, underlines its potential critical role and lends support to the claim 
that Gag mutations may depend on the background sequence of the respective 
isolate. 
The polar but uncharged T427 as the HIV-1 M-group consensus is neutral 
hydrophobic. Hence a change to asparagine or aspartic acid strongly increases the 
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hydrophilicity at this position, and such a drastic alteration in the immediate 
vicinity of a viral PR cleavage site is likely to affect processing efficiency. 
Additionally, alteration T427N has been previously recognized as a CTL escape 
mutation affecting viral replication capacity [244]. 
Of interest, p6 contains several predicted ERK-2 phosphorylation sites, i.e. 
at T456, S462, T469, T471, S473, Y484 and S499 [245], and the incorporation of 
ERK-2 into the HIV particle is thought to regulate the L-domain function of p6 
[246]. One of possible ways to regulate mono-ubiquitination is via 
phosphorylation, and it has been suggested that cellular kinases regulate 
ubiquitination and thereby the structure of p6 [245]. Structure and conformation of 
p6 are critical for maintaining its hydrophobic interface. Most p6 functions are 
suggested to occur under hydrophobic conditions near the cytoplasmic membrane 
[247]. It is therefore interesting to note that the newly described mutations 
E467V/K, 474H and Y484P in this study were located in this crucial p6 protein, 
right in the center of the phosphorylation motifs and L-domains. 
Gag amino acid 467 marks another potentially critical conserved position. 
It resides between a proline-rich region, responsible for interaction with TSG101, 
and an ALIX interaction motif. Additionally, the site is flanked by Vpr binding 
sequences. Glutamic acid at this position is the inter-subtype consensus. Therefore 
the observed change to valine would switch the character from hydrophilic to 
hydrophobic, while lysine would reverse the negative charge in the wild type to 
positive. It is currently not known what the precise contact points in the reaction 
partners are, but it is likely that either one of these drastic mutations would have 
implications for the protein-protein interaction. 
Mutation Q474L has been described to occur during the acquisition of PI 
resistance. Alone, without any accompanying alterations, it was deleterious to viral 
replication. However, with the simultaneous introduction of corresponding Gag 
cleavage-site mutations the phenotype could be rescued [203]. In line with this 
Q474Q/L has also been linked in a subtype-dependent manner to the known PI 
resistance via P453L/T [248]. In addition, the P453L/T mutation has been 
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associated with a loss of an ERK-2 phosphorylation site at T471 [248]. In our 
SHCS dataset the mutation Q474H correlated with the T427N change in 13.3% of 
cases (OR=24.4), which supports a direct connection of the p6 phosphorylation 
motifs with the sequence surrounding the p7/p1 cleavage site. As histidine can 
serve as substrate for mammalian protein kinases the mutation Q474H might 
immediately be linked to a shift of the phosphorylation event at residue T471. 
In the subtype B consensus amino acid Y484 belongs to the ALIX 
recognition motif, a site involved in the function of particle budding. Various 
alterations in the sequence of residues 482-484 have been described to affect ALIX 
binding as well as the accumulation of the Gag processing intermediates p41 and 
p25 [249, 250]. This observation highlights a connection between the p6 protein 
and the processing efficiency at the cleavage sites for p17/p24 and p24/p2. 
Additionally, residues 483 and 484 have been demonstrated to be subtype-
dependently selected CTL epitopes [251]. Moreover, the mutation L483M has 
been reported to be selected in vitro in the presence of DRV [252]. 
In line with previous studies [203, 248, 253] our data support a new role of 
p6 alterations: its phosphorylation and folding are likely to affect the efficiency of 
Gag cleavage site processing and could hence directly associate with viral fitness 
and even PI susceptibility. P6 alterations have been linked to the mutations 
affecting p17/ p24, p24/p2 and p1/p6 [203, 248-250, 253] cleavage site processing 
efficiency and we report novel connection between p6 and p7/p1 cleavage site. 
Additionally we demonstrate a potential link of PI-associated p6 mutations to 
phosphorylation of the protein.  Our data thereby indicate a key role of positions 
360, 369, 427, 467, 474, and 484. 
While mutations such as I437V have been reported to behave like primary 
protease mutations [10, 237], most other isolated Gag mutations do not confer 
resistance on their own but may rather act as amplifiers similarly to minor PI 
resistance mutations [254]. Therefore, in line with Doyon et al. [7], we speculate 
that  some Gag mutations may perform a “fine tuning” function for HIV carrying 
protease mutations e.g. with a significant fitness cost. This is in agreement with 
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Zhang et al. [255] who found them to be common and important for viral 
adaptation pathways resembling secondary protease mutations [13]. For every 
clinically evolved virus the overall sequence of Gag and Gag-Pol is crucial for 
fully assessing the role of Gag mutations in a given virus isolate [13], where both 
assembly of mature virion proteins and polyprotein cleavage are coordinated by the 
balance of the processing rate between cleavage sites. Being relatively fragile, this 
balance limits variability of cleavage site sequences and therefore possibilities of 
compensation for resistance-associated fitness loss [119, 256]. And our results 
serve as an additional argument to support background-dependent role of Gag 
mutations. 
 
7.4 Mutational patterns 
 
Mutations in HIV-1 protease responsible for the development of resistance 
against protease inhibitors are known to form certain patterns. These patterns are 
dictated by epistatic interactions between them in terms of synergistic impact on 
drug susceptibility or compensation for resistance-associated fitness loss [104, 
190]. However, Gag mutations have been identified as a second mechanism 
contributing to the decrease of PI susceptibility [197-201]. And their functionality 
crucially depends on the background sequence [13]. So this study is the first 
attempt to investigate Gag mutational clusters occurring in the isolates from SHCS 
patients. 
 Pairwise associations between the Gag and PR mutations observed in our 
dataset confirmed PR as the most interconnected region. Primary resistances 
L90M, M46I, V82A and I54V confirmed their major role in resistance and 
networking status [257-259] by showing the highest number of significant 
associations in PR. Secondary resistances in protease also demonstrated numerous 
significant associations. One of them, L33F, is a fitness-compensating alteration 
which decreases HIV susceptibility to several PI in the presence of various primary 
resistance mutations [104, 190, 260, 261].  L33F may be an important “crossroad” 
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for different resistance pathways. Such a role of L33F is supported by its direct 
contact with protease substrate / inhibitor binding residues, just like in case of 
L10I, I54LV and L90M [193]. Another secondary PI resistance mutation in 
protease A71V is located on the outer face of the protease dimer, but still was as 
interconnected as L33F and linked to the same established correlates of PI 
resistance in Gag A431V and P453L. This allows us to speculate that frequently 
observed secondary resistances represent one of the “bridges” that connect Gag 
and PR resistance patterns. We could not identify any significant link of novel PI-
associated alterations in Gag to primary resistances in PR. 
The next step was to analyze Gag-PR mutational landscape with a more 
sophisticated approach – random tree mixture models. High percentage of samples 
falling in either of proposed ordered models of accumulation of mutations with the 
bootstrap support numbers suggest that trees obtained describe interactions 
between the considered alterations within the selected patterns stably and 
comprehensively enough. Due to relatively low number of sequences included into 
the analysis we could not strictly identify the transition rates between the genetic 
events considered. But the first steps of the mutational pathways observed tended 
to represent a bottleneck, possibly related to fitness costs of further mutations. 
Bayesian network inference has demonstrated its utility in the analysis of 
HIV resistance against PI [262, 263], but it could not provide any additional data 
for our analysis. It just confirmed some of identified pairwise associations between 
the primary resistance mutations in protease. The most likely reason is that our 
dataset was not large enough to provide the algorithm with a necessary signal to 
robustly dissect the system with potentially high number of confounding effects 
and complex interactions. 
The backbone of the pattern involving Gag resistance mutation A431V and 
PR resistance mutations M46I/L, I54V and V82A observed in the current study has 
been reported by Verheyen et al. in the cohort of patients in Germany [202]. 
However, pattern reported here was broader and was primed by secondary 
resistance mutations at position 10 in PR. Additionally, A431V and I54V 
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represented rather final stages of the pattern development. By the PR mutations 
A71T/V/I the above-mentioned mutational cluster was linked to the pattern 
involving the p1/p6 cleavage site alterations P453TL and S451G/N, and which 
further involved D30N-N88D pair. In contrast to previous observations [202] 
L90M and I84V represented a branch alternative to P453T/L. For the third group 
of mutations we could not produce a reliable mutagenetic tree. This cluster seems 
to be rather isolated and includes Gag resistance I437V, major PI resistance L90M 
and three secondary mutations L10I, Q58E and G73T. In addition we show that 
resistance patterns are not limited with well-established and best-known primary 
resistances in PR and cleavage site alterations in Gag. Novel Gag mutations were 
included in the mutagenetic trees along with established Gag resistances that 
supports their potential importance in the context of PI resistance. Primary 
resistance mutations in protease seemed to initiate the development of resistance 
pattern. Then secondary resistances followed accompanied by the Gag alterations. 
L63P and L33F along with T427D/N, E467V/K, E468G, Q474H and Y484P were 
incorporated by the identified resistance patterns. 
Suggested mutational patterns identified have already found a confirmation 
for their functionality. Kolli et al. analytically demonstrated their effects: 
Mutations at position 431 decreased IDV and LPV susceptibility in the presence of 
V82A. And in the presence of L90M, mutations at positions 431 and 453 decreased 
HIV susceptibility to every PI. However, in every case enhanced resistance came 
at a cost of reduced fitness. At the same time number of secondary resistances in 
protease positively correlated with the presence of Gag alterations [240]. A431V 
[264] and I437V [10] have been shown to confer PI resistance in the absence of 
primary resistance mutations, but we could not observe such an effect in our 
experiments. We could not detect previously reported resistance effects of single 
primary resistance mutations in protease I47V, I54V and V82A as well [104, 190]. 
This discrepancy to existing data might be explained by the difference between the 
phenotyping approaches. Nijhuis et al. [10] compared phenotypic drug 
susceptibility of Gag mutant K436E-I437V in multiple-cycle MTT assay and 
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single-cycle PhenoSense assay. So for every PI tested MTT assay gave IC50 fold 
change higher than that by PhenoSense (up to 2 times). In the current study and 
previous [229] deCIPhR measured the resistance effect of primary PR mutations 
I54V and L90M lower than PhenoSense (susceptible versus resistant) [104, 190]. 
Usage of heterologous envelope in an assay may increase infectivity and help the 
virus to pass by some of the lifecycle stages blocked by PI [145, 265-267]. Signal 
reading methods have their impact dependent on sensitivity and inherent 
preciseness. Cell lines utilized influence the development of HIV infection as well 
through the cellular factors involved in the interactions with the virus [79, 80]. 
In an attempt to make the effects of Gag alterations visible we continued 
with a more complex resistance in PR L10I-M46I-I54V-A71V-V82A which has 
demonstrated measurable resistance with our assay [229]. In the resistance 
background of PR L10I-M46I-I54V-A71V-V82A we could measure fitness-
compensating effects of T427D, S451N and R452S. This is the first phenotypic 
characteristic produced for S451N and R452S previously recognized as resistance-
associated. In addition to that we confirmed the importance of T427D alteration. 
Such results make sense from the clinical and molecular point of view. On the first 
place virus accumulates resistances in PR which allow it to survive the drug 
pressure but diminish the fitness. Then (and this is supported by the mutagenetic 
trees constructed: Figure 20, Figure 21) Gag mutations occur that change Gag 
accordingly to the structure of resistant PR in order to compensate for the fitness 
loss. However, such mutated Gag might not fit well with the wild-type PR that 
would result in low fitness which we observed in our experiments in case of 
isolated Gag mutations. The structural basis for this interplay between Gag and PR 
mutations is illustrated in Figure 22. 
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Initial steps to collect and structure comprehensive data on Gag region 
alterations have already been implemented [58, 59], which may help improvement 
of current genotypic algorithms. And this study provides additional details on the 
development and interplay of Gag and PR resistance patters. 
 
7.5 Center dependence of the choice of PI-containing therapies 
 
When analyzing the relative rates of use of certain PIs for the two Swiss 
centers in this study, we noted that samples from center BS were generally 
associated with a higher exposure to NFV, SQV, and IDV. On the other hand, for 
the ZH samples ATV and DRV were more often applied. It is conceivable that one 
center might have provided to the database a higher fraction of data for patients 
with successful viral suppression and with a lower need for a new therapy change, 
thereby remaining longer on a previous drug regimen. Alternatively, since both 
centers follow Swiss treatment guidelines with their timely updates, and as both 
centers have a regular exchange among treating physicians, it is very likely that 
these differences of more conservative data set originating from BS reflect a 
sampling effect, i.e. that a larger fraction of the analyzed sequence entities stems 
from an earlier period within the time of analysis. Indeed, the analysis date of ZH 
samples was on average significantly later than for BS samples, p<0.05. The fact 
that during the period from 2004 to 2012 in ZH center 1625 patients were recruited 
versus 527 in BS also supports this point of view [268].  
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8 CONCLUSIONS 
 
This study confirms for the Swiss HIV Cohort previously published data 
from other European settings on the relevance of Gag mutations in the context of 
PI resistance. We demonstrate that 17.9% of SHCS patients carry resistance 
mutations in Gag. And since Gag is not considered by the current genotyping 
systems the overall level of PI resistance for these patients is underestimated. 
We report novel Gag mutations which accumulate in PI-treated samples 
and reside in functionally important regions of Gag. They correlated with 
previously reported resistance patterns in Gag and PR. Some of them were capable 
of increasing viral fitness in the context of resistant PR. 
The role of PI resistance mutations in Gag and PR critically depends on the 
background viral sequence. We show that secondary PI resistance mutations also 
contribute to the development of certain resistance patterns. 
Additionally our data support a new role of p6 alterations: its 
phosphorylation and folding are likely to affect the efficiency of Gag cleavage site 
processing and could hence directly associate with viral fitness and even PI 
susceptibility.  
Taken together, our data suggests the relevance of Gag sequence 
information for the routine genotyping of PI-treated patients of the SHCS.  
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9 OUTLOOK 
 
We identified novel Gag mutations A360S/P, Q369L, T427D/N, E467V/K, 
Q474H and Y484P as potentially resistance-relevant. However, of those 
alterations, we managed to characterize phenotypically only T427D mutant alone 
and in combination with PR resistances. Phenotyping experiments on the rest of 
these alterations would help to reveal their true role. They should be tested alone 
and in combination with resistant PR. Alternative approach would be reversion of 
the mutations of interest in relevant patient viruses. In this case the impact of a 
given mutation can be observed in its naturally developed backbone. Recently Dr. 
Doris Chibo from HIV Characterisation Laboratory in Doherty Institute, 
Melbourne reported 6 cases when patients were failing PI-containing therapy 
without any sufficient resistances in PR and with controlled regimen compliance. 
She kindly agreed to share corresponding Gag-PR fragments. It would be 
interesting to see if these failures could be explained by Gag alterations and if we 
could find any of our novel Gag mutations involved here. 
Different phenotyping protocols could be compared for the evaluation of 
the most frequently observed resistance patterns across Gag and PR. Nijhuis et al. 
[10] compared phenotypic drug susceptibility of Gag mutant K436E-I437V in 
multiple-cycle MTT assay and single-cycle PhenoSense assay. So for every PI 
tested MTT assay gave IC50 fold change higher than that by PhenoSense (up to 2 
times). Additionally, in the current study and previous [229] deCIPhR measured 
the resistance effect of primary PR mutations I54V and L90M lower than 
PhenoSense (susceptible versus resistant) [104, 190]. Presence of heterologous 
envelope may increase infectivity and help the virus to pass by some of the 
lifecycle stages blocked by PI [145, 265-267]. Signal reading methods have their 
impact dependent on sensitivity and inherent preciseness. Cell lines utilized 
influence the development of HIV infection as well through the cellular factors 
involved in the interactions with the virus [79, 80]. 
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In this study we concentrated our attention on subtype B isolates because 
the number of samples of other individual subtypes did not allow enough statistical 
power for the analysis even to confirm the status of primary PI resistance 
mutations in protease. In order to investigate subtype-specific aspects of Gag and 
PR resistance patterns one might try to build up a larger dataset of samples of a 
certain subtype by collecting them from different cohorts in comparable settings. 
An issue here is that different centers may use different genotyping systems that do 
not necessarily allow the extraction of Gag sequence information.     
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